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1. Introduction 
The ability of mammalian cells to respond to a wide variety of extracellular signals is 
essential for multicellular organisms during embryonic development and adult life. These 
responses are coordinated through signal transduction pathways that transduce and exchange 
information between different cells or inside the cell between different compartments. Apart 
from direct cell-cell contacts signalling to neighbouring but also distant cells occurs by 
secreted messenger molecules, such as growth factors and hormones. These molecules bind to 
their cognate receptor and thereby transmit the signal inside the target cell to finally stimulate 
a distinct biological response including cell proliferation, migration, differentiation or 
apoptosis. Consequently, deregulated signal transduction events have been recognized as the 
underlying causes of many severe human diseases such as cancer, diabetes, immune 
deficiencies and cardiovascular diseases, among many others (Hanahan and Weinberg, 2000; 
Schlessinger, 2000; Shawver et al., 2002). 
Intensive research efforts focused on the elucidation of these signalling pathways, and as 
increasingly larger numbers of cell signalling components and pathways are being identified 
and studied it has become apparent that cellular signalling pathways are not isolated from 
each other as linear tracts but are highly interconnected to form complex signalling networks. 
Reversible protein phosphorylation has been identified as a key element in signal transduction 
processes (Cohen, 2002). Phosphorylation by the combined action of a protein kinase and a 
protein phosphatase can reversibly alter the activity of an enzyme, target proteins for 
degradation or increase its stability, alter its subcellular localization or change its affinity 
towards interacting proteins. One third of all mammalian proteins can be phosphorylated, and 
the sequencing of the human genome revealed that there are approximately 520 protein 
kinases and 130 protein phosphatases encoded by human genes (Blume-Jensen and Hunter, 
2001; Manning et al., 2002). Both protein kinases and phosphatases can be subdivided into 
cellular and transmembrane molecules, and according to their substrate specificity into 
tyrosine, serine/threonine or dual specific kinases. In particular tyrosine phosphorylation has 
been early recognized as a major mechanism of transmembrane signalling (Cohen, 2002).  
1.1.  Receptor tyrosine kinases 
Receptor tyrosine kinases (RTKs) represent membrane spanning cell surface receptors 
consisting of a glycosylated extracellular domain, a single transmembrane portion and an 
intracellular domain with a protein kinase core that catalyzes the transfer of the γ-phosphate of 1. Introduction      2
bound ATP to the C-terminal domains and the tyrosine residues of exogenous substrates. 
Tyrosine kinase receptors dimerize after binding their ligands and transphosphorylate selected 
tyrosine residues of the cytoplasmic domain, generating docking sites for intracellular signal 
transducers containing phosphotyrosine interaction domains. Different transducers are 
recruited and activated depending on the sequence of the amino acids flanking the tyrosines in 
the receptor-docking sites (Blume-Jensen and Hunter, 2001; Schlessinger, 2000).  
20 subfamilies of RTKs have been described, comprising more than 50 different RTKs 
(Figure 1). In particular, the extracellular ligand-binding domain reveals the structural 
diversity of RTKs as different sequence motifs have been identified within this domain. These 
regions comprise cysteine-rich domains, EGF-like (epidermal growth factor-like) domains, 
immunoglobulin-like domains, cadherin-like domains or kringle-like domains among others 
(Figure 1) (Blume-Jensen and Hunter, 2001). 
 
 
Figure 1 Human receptor tyrosine kinases. Abbreviations: AB, acidic box; CadhD, cadherin-like domain; 
CRD, cysteine-rich domain; DiscD, discoidin-like domain; EGFD, epidermal growth factor-like domain; FNIII, 
fibronectin type III-like domain; IgD, immunoglobulin-like domain; KrinD, kringle-like domain; LRD, leucine-
rich domain. The symbols α and β denote distinct RTK subunits. (Blume-Jensen and Hunter, 2001) 
1.1.1.  The EGFR family 
The epidermal growth factor receptor (EGFR) family consists of four members, besides the 
EGFR itself and its relatives HER2/neu, HER3 and HER4. The four family members share an 
overall structure of two cysteine-rich stretches in their extracellular region. While for the 
orphan receptor HER2 no ligand has been described so far, Her3 possesses an impaired kinase 
activity due to point mutations within the catalytic domain. HER2 is only activated following 1. Introduction      3
its heterodimerization with another ligand-bound EGFR family receptor. However, HER2 is 
the preferred dimerization partner for EGFR, HER3 and HER4 (Graus-Porta et al., 1997) and 
HER2 containing dimers are responsible for strong and prolonged activation of downstream 
signalling pathways (Beerli et al., 1995; Graus-Porta et al., 1995). 
The EGFR itself represents the most prominent RTK, as it was the first cell surface receptor 
and proto-oncogene product to be identified and molecularly cloned (Downward et al., 1984; 
Ullrich et al., 1984). It has been implicated in cancer development and progression due to its 
functional role as a proto-oncogene in viruses, the pathophysiological effects of EGFR 
mutants and its overexpression in several types of cancer (Gill, 1989). In particular HER2 
gene amplification has been linked to breast cancer (Slamon et al., 1989), while the EGFR is 
frequently co-expressed with its ligands in different forms of human cancer, such as colon 
(Damstrup et al., 1999), lung and prostate (Seth et al., 1999) and epithelial cells (Dong et al., 
1999). 
1.1.2. EGF-like  ligands and receptor activation 
Under normal physiological conditions, activation of the EGFR family is controlled by spatial 
and temporal expression of their ligands, members of the EGF-related peptide growth factor 
family (Peles and Yarden, 1993; Riese and Stern, 1998). These peptides are produced as 
transmembrane precursors, and are released as soluble growth factors after proteolytical 
cleavage (Figure 2) (Massague and Pandiella, 1993). The mammalian ligands that bind the 
EGFR include epidermal growth factor (EGF), transforming growth factor α (TGF-α), 
heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), 
epiregulin (EPR) and epigen (Riese and Stern, 1998; Salomon et al., 1999; Strachan et al., 
2001). Cripto represents the most recent and a very atypical member of the EGFR ligand 
family, since it is not synthesized as a transmembrane protein but secreted (Rosa, 2002). The 
neuregulins (NRG) bind to HER3 and HER4 (NRG1 and NRG2) or only HER4 (NRG3 and 
NRG4). Together, stimulation of the EGFR and its family members by EGF and its relatives 
provides a rich and diverse signalling network (reviewed in (Yarden and Sliwkowski, 2001)). 1. Introduction      4
 
Figure 2 The EGFR family and EGF-like ligands binding to the EGFR (Harris et al., 2003). The 
neuregulins are not shown. The EGF-like ligands that are capable of stimulating the EGFR are depicted, 
including their domain structure. The characteristic feature of this family of growth factors is that they are 
synthesized as transmembrane proteins that have to be processed to become fully active. (Jorissen et al., 2003) 
  
Biophysical investigations revealed a 2:2 stoichiometry for ligand-receptor complexes 
(Lemmon et al., 1997). Recent structural studies shed new light on ligand-binding and 
receptor activation mechanisms (Garrett et al., 2002; Jorissen et al., 2003; Ogiso et al., 2002; 
Schlessinger, 2002), which support the concept of ligand-induced conformational changes 
leading to receptor dimerization rather than bridging of receptor monomers by ligand 
molecules. Receptor dimerization was shown to occur entirely receptor-mediated by a loop 
termed the "dimerization-loop", which is unique to EGFR family receptors. Deletions or 
mutations in this arm completely prevent ligand-induced EGFR activation (Garrett et al., 
2002; Ogiso et al., 2002). The dimerization arm becomes exposed only after ligand-binding as 
the consequence of a domain rearrangement within the extracellular portion of the EGFR, 
thereby regulating receptor function. In contrast, the structure of HER2, which has no direct 
ligand, demonstrated that this receptor constitutively adopts an extended configuration with 
its dimerization arm exposed (Cho et al., 2003; Garrett et al., 2003). Together with 
biophysical studies indicating only weak homodimeric interactions of HER2 receptor 
molecules this observations suggest HER2 as being able to form only heterodimers with 
ligand-activated EGFR family receptors (Garrett et al., 2002). 1. Introduction      5
1.1.3.  Met - The receptor for hepatocyte growth factor 
The Met receptor has been identified as the product of a human oncogene, tpr-met (Cooper et 
al., 1984; Park et al., 1987) containing a constitutively active Met kinase activity. The ligand 
for the Met RTK is the hepatocyte growth factor (HGF) (Giordano et al., 1989), which 
belongs to the scatter factor family. Since the original characterization as a proto-oncogene, 
the Met receptor has been shown as an important mediator of both, normal and neoplastic 
invasive growth. While the Met RTK is instrumental in developmental processes, deregulated 
Met receptor activity in many human cancers owing to genetic mutations, gene amplification, 
protein overexpression or production or HGF-dependent autocrine circuits has been shown 
(Maulik et al., 2002; Trusolino and Comoglio, 2002).  
Stimulation of the Met receptor has been linked to cellular responses associated with an 
invasive behaviour, such as cell dissociation, migration, scattering and reduced cellular 
adhesion, but also stimulation of cell proliferation and survival has been demonstrated 
(Maulik et al., 2002). The Met RTK consists of a single membrane spanning ß-subunit, which 
is linked by disulfide bridges to an extracellular α-chain. The intracellular domain comprises 
a kinase activity and 2 tyrosine residues as autophosphorylation sites enhancing the intrinsic 
kinase activity upon phosphorylation, and the multi-substrate docking site containing 2 
tyrosine residues that serve as signalling scaffolds for downstream effector molecules (Maulik 
et al., 2002). Another member of the scatter factor receptor family is the RTK RON, which is 
activated by its ligand macrophage-stimulating protein (MSP). Both the extracellular regions 
of Met and RON display structural similarities with semaphorins and plexins which together 
form  a wide family of ligand-receptor pairs that were originally identified in the nervous 
system but that are now known to be widely expressed in other cell types (Giordano et al., 
2002). 
Recent investigations identified ß-catenin as a signalling partner of the Met receptor (Hiscox 
and Jiang, 1999a; Monga et al., 2002). In the cell β-catenin exerts a dual role. It functions as a 
member of cell adherence junctions, linking E-cadherin to the cytoskeleton allowing tight 
intercellular adhesion (Conacci-Sorrell et al., 2002). On the other hand, as a member of the 
Wnt-signalling pathway, ß-catenin can translocate into the nucleus to induce gene expression 
in complex with the transcription factor TCF. Independent of Wnt signalling HGF is able to 
induce ß-catenin phosphorylation (Hiscox and Jiang, 1999b; Shibamoto et al., 1994), leading 
to dissociation of the Met-ß-catenin complex, nuclear translocation of ß-catenin and 
concomitantly induction of TCF (T-cell factor) target genes (Monga et al., 2002; Muller et al., 
2002). 1. Introduction      6
1.2.  RTK downstream signalling and protein interaction domains 
RTK activation induces specific signal transduction pathways comprising various effector 
proteins inside the cell depending on the stimulus and the cellular context. Assembly and 
regulation of these multiprotein complexes is achieved through modular protein domains that 
specifically recognize other protein domains, protein modifications, lipids or DNA sequences. 
These protein interaction domains target proteins to a specific subcellular location, provide a 
means for recognition of posttranslational protein modifications or chemical second 
messengers, control the conformation, activity and substrate specificity of enzymes (Pawson 
and Nash, 2003). In general, a protein interaction domain recognizes a core determinant, with 
flanking or non-contiguous residues providing additional contacts and an element of 
selectivity. Phosphotyrosine residues are recognized by Src-Homology 2 (SH2) and 
phosphotyrosine-binding (PTB) domains, while SH2 domains represent the most prevalent 
type of phosphotyrosine binding domains. PTB domains are not restricted to bind to 
phosphotyrosine residues as they are also capable of binding to non-phosphorylated 
sequences. Apart from phosphotyrosine residues phosphoserine residues are recognized by 
WW and 14-3-3 domains, while FHA and WD40 domains bind to phosphothreonine residues. 
In addition to phosphorylated moieties, pleckstrin homology (PH), phox homology (PHOX), 
FERM and FYVE domains bind to phosphoinositides, and SH3 and WW domains recognize 
prolin-rich motifs. Figure 3 gives an overview of different protein interaction modules and 
their binding specificities. 1. Introduction      7
 
Figure 3  Modular interaction domains as building blocks in signal transduction. Interaction domains bind 
proteins, phospholipids, or nucleic acids. A subset of such domains is illustrated and their general binding 
functions are indicated. (Pawson and Nash, 2003) 
 
A wide variety of proteins possesses both interaction domains and an enzymatic activity, such 
as the cytoplasmic kinase Src, containing SH2 domains and a kinase activity, or PLC-γ, 
containing both a SH2 domain and an phospholipase activity. In addition, signalling proteins 
consisting entirely of interaction domains have been described. Examples for these adaptor 
proteins comprise Grb2, Crk or Shc containing SH2 and SH3 domains to link activated RTKs 
to downstream signalling pathways such as the mitogen-activated protein kinases (MAPKs). 
In addition, docking proteins such as Gab1 become recruited to the cell membrane in response 
to activation of phosphatidylinositol-3 kinase (PI3K) by its PH domain (Schlessinger, 2000). 
Since RTKs are capable of recruiting a wide variety of adaptor proteins and downstream 
effectors, they have been considered as signalling platforms where specific subsets of 
signalling proteins are recruited. 
1.3.  G protein-coupled receptors 
The cell surface receptor superfamily of G protein-coupled receptors (GPCRs) forms one of 
the largest protein families found in nature. A diverse array of external stimuli including 
neurotransmitters, hormones, lipids, photons, odorants, taste ligands, nucleotides and calcium 1. Introduction      8
ions which can act through GPCRs give rise to remarkably diverse physiological functions. 
The characteristic structural feature of GPCRs, which possess no intrinsic enzymatic activity, 
are seven transmembrane helices of about 20-27 amino acids each. While the C terminus, the 
three extracellular and the three intracellular loops and the N-terminal extracellular portion 
vary in length, a weak correlation between ligand size and the length of the N-terminal 
portion has been observed, suggesting a role of this extracellular domain in ligand binding 
(Marinissen and Gutkind, 2001).  
1.3.1.  Heterotrimeric G proteins 
GPCR stimulation leads to the activation of heterotrimeric G proteins by conformational 
changes that lead to exchange of GDP for GTP bound to the Gα-subunit and dissociation into 
Gα- and Gβγ-subunits. Both the Gα and Gβγ subunits activate effector molecules including 
second messenger generating systems (Hur and Kim, 2002; Marinissen and Gutkind, 2001). 
To date 16 α, 5 β and 12 γ proteins have been cloned. G proteins are generally referred to by 
their α subunits. On the basis of amino acid similarities, four distinct families of Gα subunits 
have been recognized, namely Gαs, Gαq, Gαi and G12 (Dhanasekaran et al., 1998; Hur and 
Kim, 2002; Pierce et al., 2001).  
The signalling cascades induced by activated G proteins comprise adenylyl and guanylyl 
cyclase, calcium channels, c-Src tyrosine kinase, phosphodiesterases, phospholipases, 
GTPase-activating proteins (GAPs) such as Rap1GAP, guanine-nucleotide exchange-factors 
(GEFs) such as RhoGEF, PI3K and PKC, thereby influencing the levels of second messengers 
such as cyclic AMP and cyclic GMP, diacylglycerol, inositol (1,4,5)-triphosphate, 
phophatidyl inositol (3,4,5)-triphosphate or calcium levels or affecting e.g. stress fibre 
formation (Marinissen and Gutkind, 2001; Pierce et al., 2001).  
1.3.2.  The oncogenic potential of GPCRs and G proteins 
Many potent mitogens such as thrombin, lysophosphatidic acid (LPA), bradykinin, 
acetylcholine receptor agonists such as carbachol, angiotensin II and others stimulate cell 
proliferation by acting on their cognate GPCRs in a variety of cell types. The discovery of the 
mas oncogene, whose protein product exhibits a typical heptahelical structure, provided a link 
between cellular transformation and GPCRs (Young et al., 1986). Moreover ectopic 
expression of GPCRs such as muscarinic acetylcholine M1, M3 and M5 receptors could 
transform murine fibroblasts in an agonist-dependent fashion providing evidence that wild-
type GPCRs can be tumourigenic when exposed to an excess of locally produced or 1. Introduction      9
circulating agonists. Mutated GPCRs which are constitutively activated in an agonist-
independent fashion have transforming abilities, such as the thyroid-stimulating hormone 
receptors, which occur naturally in 30% of hyperfunctioning thyroid adenomas, suggesting a 
direct link between GPCRs and human cancer (Marinissen and Gutkind, 2001; Parma et al., 
1993). Although activating mutations are infrequent in GPCRs, these receptors can often 
contribute to neoplasia when persistently stimulated by agonists released from tumours, such 
as Gastrin-releasing peptide (GRP), neuromedin B, bradykinin, or cholecystokinin (CCK), 
which are secreted from small cell lung carcinoma which also express the cognate receptors 
and therefore exhibit autocrine or paracrine activation loops. Other GPCRs and their agonists 
have been implicated in colon adenocarcinomas, gastric hyperplasia and cancer (Marinissen 
and Gutkind, 2001). Consistent with the role for GPCRs in normal and aberrant cell growth, 
at least ten Gα subunits have been shown to harbour transforming potential, such as the 
gsp oncogene which encodes a GTPase-deficient Gαs (Marinissen and Gutkind, 2001).  
1.4.  Mitogen-activated protein kinases 
Mitogen-activated protein kinases (MAPKs) are important signal transducing enzymes 
connecting cell surface receptors to critical regulatory targets within the cell. They 
phosphorylate specific serine and threonine residues of target protein substrates thereby 
controlling cell proliferation, differentiation and transformation (Chang and Karin, 2001; 
Garrington and Johnson, 1999; Johnson and Lapadat, 2002). MAPKs also respond to 
chemical and physical stress, thereby controlling cell survival and adaptation. At least four 
distinctly regulated groups of MAPKs are expressed in mammals, extracellular-regulated 
kinase 1/2 (ERK1/2), Jun amino-terminal kinases (JNK 1/2/3), p38 proteins (p38 α/β/γ/δ) and 
ERK5 (Chang and Karin, 2001). Activation of ERK1/2 by RTKs represents the prototypic 
example for a MAPK cascade activation pathway consisting of a characteristic phosphorelay 
system in which a series of protein kinases phosphorylates and activates one another (Figure 
4).   
RTK stimulation leads to the recruitment of the adaptor protein Grb2 and association and 
activation of the RasGEF Sos, which in turn activates membrane-associated Ras. Ras in turn 
induces the serine/threonine kinase activity of the MAPK kinase kinase (MAPKKK) Raf-1  
which phosphorylates and activates the MAPK kinases 1/2 (MAPKK, MEK 1/2). MEK1/2 
finally activate ERK1/2 by phosphorylation of threonine and tyrosine residues in the 
regulatory TEY-motif (Robinson and Cobb, 1997). Subsequently ERK1/2 translocate into the 
nucleus to phosphorylate and activate transcription factors but also affect cytoplasmic or 1. Introduction      10
transmembrane effector proteins, such as regulating transmembrane protein processing (Fan 
and Derynck, 1999) by phosphorylating the intracellular domain of the metalloprotease 
ADAM17 (Diaz-Rodriguez et al., 2002; Fan et al., 2003). JNK-family MAPKs are also 
known as stress-activated protein kinases as they are activated in respone to environmental 
stress but also by radiation and growth factors. p38 becomes activated in immune cells by 
inflammatory cytokines as a crucial part of the immune response, but is also stimulated by 
hormones, GPCR agonists and cellular stress such as osmotic and heat shock or 
chemotherapeutic agents (Benhar et al., 2002b; Chen et al., 2001b; Garrington and Johnson, 
1999). Each MAPKK can be activated by more than one MAPKKK, increasing the 
complexity and diversity of MAPK signalling (Figure 4). 
The mechanisms of MAPK activation by osmotic and oxidative stress have been intensely 
studied (Kyriakis and Avruch, 2001). Previous reports implicated the downregulation of 
antagonistic phosphatases as well as the regulation of scaffolding protein function in MAPK 
activation induced by stress agents (Benhar et al., 2002b; de Nadal et al., 2002). Moreover, 
small G-proteins have been demonstrated to play a role in the activation of MAPK by osmotic 
stress (de Nadal et al., 2002).  
 
 
 
Figure 4 Mitogen activated protein kinase modules. Each module consists of a mitogen-activated proteine 
kinase kinase kinase (MKKK), a mitogen-activated proteine kinase kinase (MKK) and a MAPK. While the 
MKKs are relatively specific for their target MAPKs, MKKKs can activate one or more MKK. Activation of 1. Introduction      11
MAPKS induces activation of different targets, comprising transcription factors but also for instance other 
kinases such as the EGFR. (Johnson and Lapadat, 2002) 
1.5. RTK  transactivation 
Signal transduction pathways are organized as highly complex networks rather than linear 
signalling traits allowing communication and coordination of cellular signalling. Therefore 
increasing interest focuses on interreceptor communication mechanisms, since cross-
communication between different classes of cell surface receptors allows the integration of 
diverse extracellular stimuli to a limited number of intracellular signal transduction pathways. 
Early on, the EGFR has been shown to be activated by a variety of different stimuli in 
addition to direct stimulation with its cognate ligands, such as stress stimuli, GPCR agonists, 
integrin activation, cytokine receptors or ion channels (Fischer et al., 2003; Gschwind et al., 
2001; Prenzel et al., 2001). In addition, association of the EGFR with non-related RTKs such 
as the PDGFR has been proposed (Saito and Berk, 2001). 
1.5.1.  EGFR activation by cellular stress 
Non-physiologic stimuli exerting cellular stress are capable of activating the EGFR, which 
has been frequently recognized as a signal transducer of stress stimuli to different downstream 
pathways (Carpenter, 1999; Prenzel et al., 2001). These stimuli include UV- or γ-irradiation, 
hyperosmolarity, reactive oxygen species or membrane depolarization (Coffer et al., 1995; 
King et al., 1989; Knebel et al., 1996; Rao, 1996; Rosette and Karin, 1996; Sachsenmaier et 
al., 1994), but also cellular stress induced by chemotherapeutic agents (Benhar et al., 2002a; 
Benhar et al., 2002b). In particular chemotherapeutic-induced stress signalling pathways are 
of special clinical interest since these pathways might provide molecular explanations for 
tumours resistance towards chemotherapy. The mechanism of stress-induced EGFR and also 
MAPK activation has entirely been attributed to EGF-like ligand-independent mechanism. 
Previous reportes implicated the inactivation of phosphatases by reactive oxygen species 
(ROS), which oxidize a critical cysteine residues in the catalytic pocket of the respective 
phosphatase, in the activation of stress signalling cascades (Knebel et al., 1996). Inhibition of 
negative regulation then results in an equilibrium shift from the non-phosphorylated to the 
phosphorylated state of the RTK (Meng et al., 2002; Salmeen et al., 2003). In addition, 
ligand-independent receptor activation has been suggested to involve non-specific clustering 
and internalization of the EGFR (Rosette and Karin, 1996).  1. Introduction      12
1.5.2.  EGFR signal transactivation  
EGFR signal transactivation by GPCRs has been originally described by Daub and colleagues 
(Daub et al., 1996). Treatment of rat fibroblasts with lysophophatidic acid, endothelin-1 (ET-
1) or thrombin leads to rapid and transient EGFR phosphorylation and subsequent activation 
of downstream signalling events such as mitogen-activated protein kinase (MAPK) 
phosphorylation or c-fos gene expression, which critically depend on EGFR function. 
Thereafter, various studies demonstrated that GPCR-induced EGFR signal transactivation 
occurs in a variety of cell types (Fischer et al., 2003; Gschwind et al., 2001). 
Since no EGF-like ligands could be detected in conditioned cell culture media of GPCR 
ligand-stimulated cells, the transactivation mechanism was attributed to a ligand-independent 
and therefore intracellular mechanism. Different cytosolic signal transduction proteins have 
been implicated in the transactivation process. 
Src-family tyrosine kinases have been suggested as both upstream and downstream mediators 
of the EGFR in the GPCR-induced transactivation. Besides Src kinases, the serine/threonine 
kinase PKC has been frequently suggested to be involved in EGFR signal transactivation. 
Moreover in different cellular systems the intracellular Ca
2+-concentration and the Ca
2+-
regulated tyrosine kinase Pyk2 have been discussed as a mediator of EGFR signal 
transactivation (Eguchi et al., 1998; Keely et al., 2000; Soltoff, 1998; Venkatakrishnan et al., 
2000; Zwick et al., 1997). Together, these reports did not clearly depict the role of cytosolic 
signalling proteins but rather suggest several cytoplasmic signalling molecules as mediators of 
the EGFR signal transactivation pathway depending on the cellular system and the signalling 
context.  
Although different investigations suggested a ligand-independent intracellular signalling 
mechanism (Daub et al., 1997; Eguchi et al., 1998; Tsai et al., 1997), Prenzel and colleagues 
were the first to demonstrate the metalloprotease-mediated processing of the EGF-like ligand 
HB-EGF and therefore a ligand-dependent mechanism in EGFR signal transactivation 
(Prenzel et al., 1999), providing a convergence point for intracellular signalling proteins. 
Blocking both proHB-EGF and metalloprotease function abrogated GPCR stimulated EGFR, 
Shc and MAPK phosphorylation, revealing the involvement of zinc-dependent 
metalloproteases and the EGF-like ligand HB-EGF in the transactivation pathway. As 
processed HB-EGF is retained in the heparan sulphate proteoglycan matrix, the released 
ligand could not be detected in the cell culture supernatant. This signalling pathway was 
termed triple-membrane-passing signal (TMPS) as the stimulus is travelling three times 
through the membrane before it finally activates intracellular effector pathways. Since this 1. Introduction      13
initial discovery, many reports revealed the broad relevance of this signalling mechanism 
within a variety of cellular systems and, importantly, pathophysiological signalling situations. 
As transmembrane ligand precursor molecules are a characteristic feature of the EGFR and its 
relatives, this transactivation mechanism is likely to be a common activation mechanism of 
the EGFR and the ErbB family members. 
 
 
Figure 5 Model of EGFR signal transactivation according to the triple-membrane-passing signal (TMPS). 
GPCR stimulation induces upregulation of a metalloprotease activity leading to ectodomain-cleavage of EGF-
like growth factor precursor molecules. Subsequent release of the mature growth factor stimulates EGFR kinase 
activity transducing the GPCR signal finally inside the cell to stimulate EGFR characteristic downstream 
signalling pathways such as MAPK, PLC-γ, STAT or PI3K activation (Fischer et al., 2003). 
 
1.5.3.  ADAM family metalloproteases 
Metalloproteases of the ADAM (a disintegrin and a metalloprotease domain) family consist of 
a cytoplasmic domain of variable length, a single transmembrane domain, and on the 
extracellular side of a catalytic, a cysteine rich and a disintegrin domain (Werb and Yan, 
1998). The latter have adhesive properties by allowing interactions with integrins, heparan 
sulphate proteoglycans and extracellular matrix (ECM) proteins, while the metalloprotease 
domain can induce ectodomain shedding and cleavage of ECM. In addition the inactive pro-
form contains a pro-domain which renders the protease inactive by blocking the essential zinc 
atom in the catalytic site by binding with a cysteine residue (White, 2003).  
Members of the ADAM family of zinc-dependent metalloproteases have been frequently 
implicated in the processing of proEGF-like ligands and various other transmembrane 1. Introduction      14
proteins (Werb and Yan, 1998; White, 2003). Studies using fibroblasts derived from TACE 
knock-out mice implicated ADAM17 in the release of TGF-α and other EGF-like ligands as 
well as the constitutive availability of these growth factors (Peschon et al., 1998; Sunnarborg 
et al., 2002). Furthermore, ADAM9 has been shown to release proHB-EGF after treatment of 
VeroH cells with tetra-doceanoyl-phorbol-13-acetate (TPA) (Izumi et al., 1998), while in the 
same cellular system LPA-stimulated processing of proHB-EGF is independent of ADAM9 
(Umata et al., 2001), suggesting that proHB-EGF sheddases are defined by both the cellular 
context and the stimulus. The critical role of ADAM proteases in EGFR signal transactivation 
has been shown by Gschwind et al. who demonstrated LPA-induced processing of   
amphiregulin by ADAM17 in head and neck squamous cell carcinoma cells (Gschwind et al., 
2003). Lemjabbar et al. reported that in the same cellular system different protease/ligand 
combinations can act as transducers of GPCR-induced EGFR stimulation (Lemjabbar and 
Basbaum, 2002; Lemjabbar et al., 2003). ADAM10 processing proHB-EGF has been 
implicated in EGFR signal transactivation in Cos7 cells (Yan et al., 2002). These findings 
provide evidence for the high diversity of signalling components employed in EGFR signal 
transactivation.  
So far the identity of the signalling elements in between the GPCRs and the ADAM proteases 
remain elusive. Mechanistical studies on the regulation of cell surface shedding events 
implicated the MAPKs extracellular-regulated kinase 1/2 in the processing of TGF-α upon 
treatment with PGDF, FGF or EGF, while p38 was shown to control basal TGF-α shedding 
(Fan and Derynck, 1999). Moreover, different reports demonstrated phosphorylation of the 
intracellular domain of ADAM17 in response to TPA and growth factors (Diaz-Rodriguez et 
al., 2002; Fan et al., 2003). In contrast, Black and coworkers reported that the cytoplasmic tail 
of ADAM17 is dispensable for TPA-stimulated release of TNF-α and other substrates (Reddy 
et al., 2000). 
1.5.4.  Receptor cross-talk beyond EGFR signal transactivation 
Cross-talk between cell surface receptors can occur in several different ways. The most direct 
mechanism is receptor heterodimerization which is well described for members of the EGFR 
family (Yarden, 2001) or Met and its relative RON (Follenzi et al., 2000). Also less related 
receptors have been shown to be able to associate such as EGFR and PDGFR (Saito et al., 
2001) or Met and semaphorin receptors (Giordano et al., 2002). In the case of EGFR and the 
Met receptor, cross-communication has been reported to occur on different levels: EGFR 
signal transactivation induces metalloprotease-mediated ectodomain shedding of Met (Nath et 1. Introduction      15
al., 2001) and aberrant EGFR activation has been shown to elevate Met expression and 
phosphorylation in thyroid carcinoma cells (Bergstrom et al., 2000). EGFR function has been 
implicated in HGF-induced hepatocyte proliferation (Scheving et al., 2002), and a possible 
heterodimer formation of both receptors has been suggested (Jo et al., 2000; Pai et al., 2003).  
While EGFR signal transactivation represents the most prominent GPCR-RTK cross-talk 
mechanism, GPCR-induced RTK activation is not restricted to the EGFR. Other RTKs have 
been shown to be activated in response to GPCR stimulation, comprising the IGF-1 receptor 
(Rao et al., 1995), Trk receptor (Lee and Chao, 2001), platelet-derived growth factor receptor 
(PDGFR) (Herrlich et al., 1998; Linseman et al., 1995) and the vascular endothelial growth 
factor receptor (VEGFR) (Thuringer et al., 2002). In contrast to metalloprotease-mediated 
EGFR signal transactivation involving the release of EGF-like ligands, the transactivation 
mechanism described so far for other RTKs does not involve proteolysis of ligand precursor 
molecules, as their cognate growth factors are in most cases secreted rather than 
transmembrane molecules. Different mechanistic concepts have been proposed for ligand-
independent RTK transactivation. Similar to early reports on EGFR signal transactivation 
cytoplasmic tyrosine kinases in particular of the Src family have been implicated in RTK 
transactivation, such as GPCR-induced activation of the Trk or  FLK-1  receptor (Lee and 
Chao, 2001; Tanimoto et al., 2002). Moreover, increasing evidence implicates reactive 
oxygen species (ROS) as signalling intermediates in RTK activation (Bae et al., 1997; Rhee et 
al., 2000; Saito and Berk, 2001; Sundaresan et al., 1995; Ushio-Fukai et al., 2001).  
1.5.5.  Reactive oxygen species in signal transduction  
An increase in ROS levels has been reported not only after RTK but also in response to GPCR 
stimulation in vascular smooth muscle cells or endothelial cells (Holland et al., 1998; 
Patterson et al., 1999). Angiotensin II-induced EGFR transactivation was shown to be blocked 
by reducing agents and therefore proposed to involve ROS in vascular smooth muscle cells 
(Ushio-Fukai et al., 2001). Interestingly, activation of ERK1/2 in HeLa cells  and thrombin-
induced cell proliferation in vascular smooth muscle cells was H2O2-dependent (Chen et al., 
1995; Patterson et al., 1999). Similar to cellular stress exerted by exogenous reactive oxygen 
species such as stimulation with hydrogen peroxide, intracellular produced ROS are able to 
inactivate phosphatases thereby leading to an alteration of the tyrosine kinase/phosphatase 
balance towards the phosphorylated state. Several recent reports have demonstrated that 
exogenous oxidants or oxidants generated by peptide growth factor binding can reversibly 
oxidize and hence inactivate protein tyrosine phosphatases (PTPs) (Blanchetot et al., 2002; 
Meng et al., 2002; Rao and Clayton, 2002). In contrast to ROS as a cellular stress factor, the 1. Introduction      16
production of radicals in cell signalling requires a spatial and temporal tightly controlled 
mechanism, allowing both a rapid and transient production but also within a restricted area 
and within a limited period of time to ensure specificity. Besides PTPs, G proteins of the Gαi/o 
subtype have been reported to be redox-sensitive (Nishida et al., 2000; Nishida et al., 2002). 
ROS-induced G protein activation is restricted to these pertussis toxin-sensitive Gα subunits 
as they contain a cysteine residue which is susceptible to oxidation and induces in the 
oxidized state activation of the G protein subunit (Nishida et al., 2002). Sequence alignments 
demonstrated that this particular cysteine residue is not present in other Gα subunits. 
Interestingly, elevated ROS levels have been associated with a malignant phenotype 
(Szatrowski and Nathan, 1991). 
1.5.6. Growth  factor-stimulated  ROS production : NADPH oxidases 
Receptor-mediated production of hydrogen peroxide (H2O2) has been studied mostly in 
phagocytic leukocytes. In these cells, the one-electron reduction of molecular oxygen by a 
multicomponent reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase system (Nox) generates superoxide (O2
⋅-), which is spontaneously or enzymatically 
converted to H2O2. While almost all classical oxidases generate superoxide anions, most 
aspects of signalling have been linked to the more stable derivative, hydrogen peroxide. H2O2 
meets all the criteria for an intracellular messenger, as its is a small, diffusible and ubiquitous 
molecule that can be synthesized and destroyed rapidly in response to external stimuli. Since 
the initial observation that insulin induces the generation of H2O2 in adipose cells (May and 
de Haen, 1979), the intracellular generation of this molecule has been detected in various 
nonphagocytic cells in association with receptor stimulation (Finkel, 2003; Lambeth, 2002; 
Rhee et al., 2000). The structure of Nox enzyme complexes in non-phagocytic cells is not 
well defined. However, homologues of the catalytic subunit gp91
phox have been identified, 
while the role of other components of the complex is ill defined. The small G protein Rac is 
involved in the regulation of the Nox complex in phagocytic cells and has also been 
implicated in its regulation in nonphagocytic cells (Bae et al., 2000; Sundaresan et al., 1996; 
Yeh et al., 1999). Importantly, overexpression of Nox1 has been demonstrated to induce 
transformation of NIH-3T3 cells (Suh et al., 1999). Moreover, overexpression of Nox1 
induced tumour formation in mice (Arnold et al., 2001), and recently Arbiser and colleagues 
reported that tumours induced by Nox1 expression enhanced angiogenesis in a ROS-
dependent manner (Arbiser et al., 2002). 1. Introduction      17
1.6.  Aim of the study 
Aim of this study is to investigate cell surface receptor cross-talk mechanisms in cellular 
signalling and their potential role in human cancer. To address this question, three different 
objectives are of special interest. 
 
1. Recent advances in understanding the underlying molecular mechanisms of EGFR signal 
transactivation by the discovery of metalloprotease-induced EGF-like ligand precursor 
processing raised the question whether this mechanistic concept is involved in human cancer 
cell lines. Different cell lines derived from both non-small cell lung carcinoma (NSCLC) and 
pancreatic carcinoma are investigated as model systems for the ligand-dependent EGFR 
signal transactivation mechanism and for cellular responses dependent on this pathway which 
are associated with a malignant phenotype such as cell proliferation. 
 
2. Moreover, apart from GPCR agonists other heterogeneous stimuli are known to induce 
EGFR phosphorylation, including stress stimuli such as osmotic or oxidative stress, 
mechanical stretch or UV- or γ-irradiation. Given the increasing significance of ligand-
induced EGFR activation mechanisms this study addresses the relevance of EGF-like ligand 
processing for EGFR activation in response to cellular stress stimuli. Since chemotherapeutic 
agents are known to induce stress signalling cascades within the cell, the potential 
involvement of such a signalling pathway in cellular responses of tumour cells to 
chemotherapy is examined. 
 
3. Apart from EGFR signal transactivation cross-talk between GPCRs and other RTKs has 
been reported but mainly in endothelial or vascular smooth muscle cells or cells of neuronal 
origin. Therefore during the investigations of EGFR signal transactivation in NSCLC and 
pancreatic carcinoma cell lines the potential cross-communication of GPCRs and other RTKs 
is investigated in these epithelial cell types with respect to the cross-talk mechanism and 
downstream signalling. 2. Materials and Methods    18 
2.  Materials and Methods 
2.1. Materials 
2.1.1.  Laboratory chemicals and biochemicals 
A c r y l a m i d e            S e r v a ,   H e i d e l b e r g  
Agar            Difco,  Detroit,  USA 
Agarose           BRL,  Eggenstein 
Ampicillin           Roche,  Mannheim 
Aprotinin           Sigma,  Taufkirchen 
APS (Ammonium peroxodisulfate)        Bio-Rad,  München 
ATP  (Adenosine  3´-triphosphate)        Pharmacia,  Freiburg 
Batimastat           British  Biotech,  Oxford,   
         U K  
Bisacrylamide         Roth,  Karlsruhe 
Bromphenol  blue          Sigma,  Taufkirchen 
BSA  (Bovine  serum  albumin)        Sigma,  Taufkirchen 
Coomassie  G250          Serva,  Heidelberg 
Deoxynucleotides  (dG/A/T/CTP)        Roche,  Mannheim 
Dideoxynucleotides  (ddG/A/T/CTP)      Pharmacia,  Freiburg 
DTT  (Dithiothreitol)          Sigma,  Taufkirchen 
Ethidium  bromide          Sigma,  Taufkirchen 
Heparin           Sigma,  Taufkirchen 
HEPES (N-(2-Hydroxyethyl)piperazine-N`-     Serva,  Heidelberg 
  (2-ethanesulfonic acid)) 
IPTG (Isopropyl β-D-1-thiogalactopyranoside)      Biomol,  Hamburg 
L-Glutamine           Gibco,  Eggenstein 
Leupeptin           Sigma,  Taufkirchen 
Lipofectamine®          Gibco,  Eggenstein 
Lysozyme           Sigma,  Taufkirchen 
Marimastat           Sugen  Inc.,  CA,  USA 
MBP  (Myelin  basic  protein)         Sigma,  Taufkirchen 
Mineral  oil           Sigma,  Taufkirchen 
MOPS (3-Morpholinopropanesulfonic  acid)     Biomol,  Haub 
PMSF  (Phenylmethanesulfonyl  fluoride)       Sigma,  Taufkirchen 
pNPP  (p-Nitrophenyl  phosphate)      Sigma,  Taufkirchen 
Polybrene  (Hexadimethrine  bromide)       Sigma,  Taufkirchen 
PD98059           Alexis,  Grünberg 
PEG (Polyethylene glycol) 4000, 6000         Serva, Heidelberg 
Ponceau  S           Sigma,  Taufkirchen 
PP2            Calbiochem,  Bad  Soden 
PTX  (Pertussis  toxin)        List,  Campbell,  USA 
Salmon  sperm  DNA          Sigma,  Taufkirchen 
SDS  (Sodium  dodecyl  sulfate)        Roth,  Karlsruhe 
Sodium  azide           Serva,  Heidelberg 
Sodium  fluoride          Sigma,  Taufkirchen 
Sodium  orthovanadate         Aldrich,  Steinheim 
Scintillation  cocktail  (Rotiszint®ecoplus)       Roth,  Karlsruhe 2. Materials and Methods    19 
TEMED (N,N,N',N'-Tetramethylethylenediamine)      Serva, Heidelberg 
TPA (Tetradecanoyl-phorbol-13-acetate)       Sigma,  Taufkirchen 
Triton  X-100           Serva,  Heidelberg 
Tween  20,  40           Sigma,  Taufkirchen 
Tyrphostin  AG1478          Alexis,  Grünberg 
All other chemicals were purchased from Merck (Darmstadt). 
2.1.2. Enzymes 
Alkaline  Phosphatase        Roche,  Mannheim 
Restriction  Endonucleases         Pharmacia,  Freiburg 
Roche, Mannheim 
NEB, Frankfurt/ Main 
MBI Fermentas, St. Leon-
 Rot 
T4-DNA  Ligase          Roche,  Mannheim 
T7-DNA  Polymerase          Pharmacia,  Freiburg 
Taq-DNA  Polymerase         Roche,  Mannheim 
Takara, Japan 
Trypsin           Gibco,  Eggenstein 
2.1.3. Radiochemicals 
[γ-32P] ATP >5000 Ci/mmol 
[a-33P] dATP 2500 Ci/mmol 
L-[35S] Methionine >1000 Ci/mmol 
All radiochemicals were obtained from PerkinElmer Life Sciences, Köln. 
2.1.4.  „Kits" and other materials 
Cell culture materials    Greiner, Solingen 
Nunclon, Dänemark 
Falcon, U.K. 
Cellulose nitrate 0.45 µm             Schleicher & Schüll, Dassel 
Dowex  AG1-X8          Bio-Rad,  München 
E C L   K i t            P e r k i n E l m e r ,   K ö l n  
Glutathione-Sepharose          Pharmacia,  Freiburg 
H y p e r f i l m   M P           A m e r s h a m ,   U S A  
Micro BCA Protein Assay Kit           Pierce, Sankt Augustin 
Parafilm  Dynatech,          Denkendorf 
Poly Prep® Chromatography  columns       Bio-Rad,  München 
Protein  A-Sepharose          Pharmacia,  Freiburg 
Protein  G-Sepharose          Pharmacia,  Freiburg 
QIAquick Gel Extraction Kit (50)        Qiagen,  Hilden 
QIAquick  PCR  Purification  Kit        Qiagen,  Hilden 
QIAGEN  Plasmid  Maxi  Kit         Qiagen,  Hilden 
Random-Primed  DNA  Labeling  Kit        Pharmacia,  Freiburg 
Sephadex G-50 (DNA Quality)       Pharmacia,  Freiburg 
Sterile filter 0.22 µm, cellulose acetate       Nalge  Company,  USA 
Sterile filter 0.45 µm, cellulose acetate       Nalge  Company,  USA 
Transwells           Corning,  New  York,  USA 
W h a t m a n   3 M M           W h a t m a n ,   U S A  2. Materials and Methods    20 
2.1.5.  Growth factors and ligands 
Anisomycin           Calbiochem 
Amphiregulin           R&D  Systems 
Bradykinin           Calbiochem 
EGF  (murine)           Toyoba,  Japan 
H G F   ( h u m a n )          C a l b i o c h e m  
All other growth factors and ligands were purchased from Sigma. 
2.1.6. Media  and  buffers 
Medium for E.coli 
 
LB-Medium     1.0 % Tryptone 
0.5 % Yeast Extract 
1.0 % NaCl 
pH 7.2 
 
2xYT-Medium   1.6 % Tryptone 
1.0 % Yeast Extract 
1.0 % NaCl 
pH 7.2 
 
When necessary the following antibiotics were added to the media after autoclavation: 
 
Ampicillin 100 µg/mL 
Kanamycin 100 µg/mL 
Chloramphenicol 30 µg/mL 
 
LB-plates additionally contained 1.5% Agar. 
2.1.7.  Cell culture media 
All cell culture media and additives were from Gibco (Eggenstein), fetal calf serum (FCS) as 
purchased from Sigma. 
 
Dulbecco’s modified eagle medium (DMEM) with 4.5 mg/mL glucose, 2 mM L-glutamine, 1 
mM sodium pyruvate. 
 
Eagle´s minimum essential medium (EMEM) supplemented with 2 mM L-glutamine, 0.1 mM 
non-essential amino acids and 1 mM sodium pyruvate. 
 
Freeze medium: 90% heat-inactivated FCS, 10% DMSO. 
2.1.8.  Stock solutions for buffers 
BBS (2x)       50 mM BES 
280 mM NaCl 
1.5 mM Na2HPO4 
pH 6.96 (NaOH) 
 
HBS (2x)       46 mM HEPES pH 7.5 2. Materials and Methods    21 
274 mM NaCl 
1.5 mM Na2HPO4 
pH 7.0 
 
Denhardt (100x)     2.0 % Polyvinylpyrollidon 
2.0 % Ficoll 
2.0 % BSA 
 
DNA loading buffer (6x)   0.25 % Bromphenol blue 
0.25 % Xylencyanol 
30.0 % Glycerol 
100.0 mM EDTA pH 8.0 
 
Laemmli buffer (2x)    187.5 mM Tris/HCl pH 6.8 
6.0 % SDS 
30.0 % Glycerol 
0.01 % Bromphenol blue 
5.0 % ß-Mercaptoethanol 
 
NET (1x)       150.0 mM NaCl 
5 mM EDTA 
50 mM Tris 
0.05 % Triton X-100 
pH 7.4 (HCl) 
 
PBS       13.7  mM  NaCl 
2.7 mM KCl 
80.9 mM Na2HPO4 
1.5 mM KH2PO4, pH 7.4 (HCl) 
 
SD-Transblot      50.0 mM Tris/HCl pH 7.5 
40.0 mM Glycine 
20.0 % Methanol 
0.004 % SDS 
 
“Strip”  buffer      62.5  mM Tris/HCl pH 6.8 
2.0 % SDS 
100 mM ß-Mercaptoethanol 
SSC (20x) 3.0 M NaCl 
0.3 M Sodium citrate 
 
TAE (10x)       400 mM Tris/Acetate 
10 mM EDTA 
pH 8.0 (Acetic acid) 
 
TE10/0.1       10.0 mM Tris/HCl pH 8.0 
0.1 mM EDTA pH 8.0 
 
Tris-Glycine-SDS (10x)   248.0 mM Tris/HCl pH 7.5 
1918.0 mM Glycine 
1.0 % SDS 2. Materials and Methods    22 
2.1.9. Bacterial  strains,  cell lines and antibodies 
2.1.9.1. E.coli  strains 
E.  coli      Description         Origin/  Reference 
 
DH5aF’     F’/endA1 hsd17 (rk-mk-),supE44,      Genentech, 
recA1, gyrA (Nal), thi-1,         San Francisco, USA 
(lacZYA-argF  
 
CJ236      dut-,  ung-,  thi-,  relA-        (Kunkel,  1985) 
 
2.1.9.2. Cell  lines 
Cell  Line     Description         Origin/  Reference 
 
COS-7    African  green  monkey,  SV40-    Genentech   
transformed kidney fibroblasts 
 
HEK-293     T Human embryonic kidney fibroblasts,     ATCC CRL-1573  
transformed with adenovirus Typ V DNA 
 
DAN-G   Human  pancreatic  carcinoma     RZPD 
 
All other cell lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, USA) and grown as recommended by the supplier. 
2.1.9.3. Antibodies 
The following antibodies were used in immunoprecipitation experiments, as primary 
antibodies in immunoblot analysis or for staining of cell surface proteins in FACS analysis.  
 
Antibody     Description/  Immunogen       Origin/  Reference   
 
P-Tyr (4G10)    Mouse, monoclonal; recognizes phospho-     UBI, Lake Placid  
(3)-tyrosine residues 
EGFR      Sheep,  polyclonal/  part  of cytoplasmic domain   UBI    
   of  the  human  EGFR 
EGFR (108.1)   Mouse, monoclonal/ ectodomain of the human   (Daub et al., 1997) 
EGFR 
HER2/neu     Rabbit, polyclonal/ C-terminal peptide of human   (Daub  et al., 1996)
   H E R 2 / n e u  
Akt1/2     Rabbit, polyclonal/ AA 345-480 of human Akt1   Santa Cruz, USA 
SHC      Mouse,  monoclonal        Santa  Cruz 
SHC      Rabbit,  polyclonal/  220  AA at C-terminus of   (Daub et al., 1997) 
human SHC 
Gab1      Rabbit,  polyclonal/  AA 23-189 of human Gab1   (Daub et al., 1997) 
P-ERK     Rabbit, polyclonal; recognizes phospho-p44/p42   NEB, Frankurt/M. 
(Thr-202/ Tyr-204) MAPK 2. Materials and Methods    23 
P-p38      Rabbit, polyclonal; recognizes phospho-p38   NEB 
(Thr-180/Tyr-182) MAPK 
ADAM17/TACE   Rabbit, polyclonal/ AA 807-823 of human     Chemicon, Hofheim 
TACE 
HB-EGF   Goat, polyclonal/ recombinant, human HB-EGF   R&D  Systems,   
       W i e s b a d e n  
ERK2      (C-14) Rabbit, polyclonal/ peptide at C-terminus   Santa Cruz ERK2 
of rat ERK2  
(K-23)     Rabbit, polyclonal/ peptide from sub-domain XI   Santa Cruz  
   of  rat  ERK2 
ERK2 HA   Mouse, monoclonal; recognizes the influenza   Babco,  California, 
hemagglutinin  epitope       USA 
VSV (P5D4)   Mouse, monoclonal; recognizes an epitope of   Roche,  Mannheim, 
eleven AA derived from the vesicular stomatits 
virus glycoprotein VSV-G 
p38 (C-20)     Rabbit, polyclonal/ peptide at C-terminus of   Santa Cruz 
   murine  p38 
h-Met (C-28)    Rabbit, polyclonal/ peptide at C-terminus of   Santa Cruz 
human c-Met 
 
For western blot secondary antibodies conjugated with horseradish peroxidase (HRP) were 
utilized. 
 
Antibody      Dilution       Origin     
 
Goat   anti-mouse     1 : 10,000         Sigma 
Goat anti-sheep     1 : 25,000         Dianova, Hamburg 
Goat anti-rabbit     1 : 25,000         BioRad, München 
 
The FITC-conjugated rabbit anti-goat and FITC-conjugated goat anti-mouse secondary 
antibodies for flow cytometry were obtained from Sigma. 
 
2.1.10. Plasmids  and  oligonucleotides 
2.1.10.1. Primary  vectors 
Vector     Description        Origin/  Reference 
 
pcDNA3       Mammalian expression vector, Ampr,   Invitrogen, 
CMV promotor, BGH poly A,     USA 
high copy number plasmid 
 
pLXSN   Expression vector for retroviral gene   Clontech, Palo Alto, 
transfer, Ampr, Neor, ori from pBR322, USA 
5’-LTR and 3’-LTR from MoMuLV, 
SV40 promotor 
pLXSN-ESK      Modified pLXSN vector with multipe   J. Ruhe 
cloning site from pBluescript 
 
pRK5       Expression  vector,  Ampr, CMV     Genentech 2. Materials and Methods    24 
Promoter, SV 40 poly A, high 
copy number plasmid 
2.1.10.2. Constructs 
Vector     Description        Reference   
 
pcDNA3-HA-ERK2   cDNA of ERK2 in pcDNA3,     (Daub  et al., 1997) 
HA-Tag 
 
pcDNA3-M1R     cDNA of human M1R in pcDNA3     (Daub et al., 1997) 
 
pLXSN-M1R   cDNA of human M1R in pLXSN    (Prenzel et al.,  
        1999)   
pcDNA3-proHB-EGF-VSV  cDNA of human proHB-EGF in pcDNA3  (Prenzel et al.,  
          1999) 
pGEX-cJun      cDNA of human c-Jun in pGEX  
 
2.1.10.3. siRNA-Oligonucleotides 
siRNA     Description/Sequence     Reference   
 
gl2     directed  against  firefly  luciferase    S. Hart, this group 
    CGUACGCGGAAUACUUCGAdTdT 
 
ADAM9   AAUCACUGUGGAGACAUUUGCdTdT,    S. Hart, this group 
    AAACUUCCAGUGUGUAGAUGCdTdT 
 
ADAM10    AAUGAAGAGGGACACUUCCCUdTdT,  S. Hart, this group 
    AAGUUGCCUCCUCCUAAACCAdTdT 
 
ADAM12    AACCUCGCUGCAAAGAAUGUGdTdT,  S. Hart, this group 
    AAGACCUUGATACGACUGCUGdTdT  
 
ADAM15    AACUCCAUCUGUUCUCCUGACdTdT  S. Hart, this group 
    AAAUUGCCAGCUGCGCCCGUCdTdT  
 
ADAM17    AAGUUUGCUUGGCACACCUUdTdT  S. Hart, this group 
    AAGUAAGGCCCAGGAGUGUUdTdT 
    AACAUAGAGCCACUUUGGAGAdTdT   
 
2.2.  Methods in molecular biology 
2.2.1.  Plasmid preparation for analytical purpose 
Small amounts of plasmid DNA were prepared as described previously (Lee and Rasheed, 
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2.2.2.  Plasmid preparation in preparative scale 
For transfection experiments of mammalian cells DNA of high quality was prepared using 
Qiagen Maxi-Kits (Qiagen, Hilden) according to the manufacturers´ recommendations. 
2.3.  Enzymatic manipulation of DNA 
2.3.1.1.  Digestion of DNA samples with restriction endonucleases 
Restriction endonuclease cleavage was accomplished by incubating the enzyme(s) with the 
DNA in appropriate reaction conditions. The amounts of enzyme and DNA, the buffer and 
ionic concentrations, and the temperature and duration of the reaction was adjusted to the 
specific application according to the manufacturers´recommendations. 
2.3.1.2.  Dephosphorylation of DNA 5'-termini with calf intestine alkaline phosphatase 
(CIAP) 
Dephosphorylation of 5´-termini of vector DNA in order to prevent self-ligation of vector 
termini. CIP catalyzes the hydrolysis of 5´-phosphate residues from DNA, RNA, and ribo and 
deoxyribonucleoside triphosphates. The dephosphorylated products possess 5´-hydroxyl 
termini. 
For dephosphorylation 1-20 picomoles of DNA termini were dissolved in 44 µL deionized 
water, 5 µL 10x reaction buffer (500 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.5) and 1 µL 
CIP (1 U/µL). The reaction was incubated 30 min at 37°C and stopped by heating at 85°C for 
15 minutes. 
2.3.1.3.  DNA insert ligation into vector DNA 
T4 DNA Ligase catalyzes the formation of a phosphodiester bond between juxtaposed 5'-
phosphate and 3'-hydroxyl termini in duplex DNA. T4 DNA Ligase thereby joins 
doublestranded DNA with cohesive or blunt termini. 
In a total volume of 10 µL the digested, dephosphorylated and purified vector DNA (200 ng), 
the foreign DNA to be inserted, 1 µL 10x T4 DNA Ligase buffer (0.66 M Tris/HCl pH 7,5, 50 
mM MgCl2, 50 mM DTT, 10 mM ATP) and 1 µL T4 DNA Ligase (2 U for sticky ends and 4 
U for blunt ends) were mixed. The reaction was incubated at 15°C overnight. T4 DNA Ligase 
was inactivated by heating the reaction mixture at 65°C for 10 minutes. The resulting ligation 
reaction mixture was directly used for bacterial transformation. 
2.3.1.4. Agarose  gel  electrophoresis 
Agarose gel electrophoresis is a simple and highly effective method for separating, 
identifying, and purifying 0.5- to 25 kb DNA fragments. 0.6-2%, horizontal agarose gels with 
1x TAE electrophoresis buffer were used for separation. The voltage was set typically to 1-10 
V/cm of gel. Gels were stained by covering the gel in a dilute solution of ethidium bromide 
(0.5 µg/mL in water) and gently agitating for 30 min and destained by shaking in water for an 
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2.3.1.5.  Isolation of DNA fragments using low melting temperature agarose gels 
Following preparative gel electrophoresis using low melting temperature agarose, the gel slice 
containing the band of interest was removed from the gel. This agarose slice was then melted 
and subjected to isolation using the QIAquick Gel Extraction Kit (Qiagen). 
2.3.2.  Introduction of plasmid DNA into E.coli cells 
2.3.2.1.  Preparation of competent cells 
Competent cells were made according to the procedure described before (Chung and Miller, 
1988). For long-term storage competent cells were directly frozen at –70°C. Transformation 
frequency ranged between 106 and 107 colonies/µg DNA. 
2.3.2.2.  Transformation of competent cells 
100 µL competent cells were added to 10 µL ligation mix and 20 µL 5x KCM (500 mM KCl, 
150 mM CaCl2, 250 mM MgCl2) in 70 µL H2O and incubated on ice for 20 min. Upon 
incubation at room temperature for 10 min 1 mL LB medium was added and incubated 45 
min at 37°C with mild shaking to allow expression of the antibiotic resistance gene. 
Transformants were selected on appropriate plates. 
2.3.3. Oligonucleotide-directed  mutagenesis 
A DNA sequence can be specifically altered by synthesizing the desired sequence change 
within an oligonucleotide, and then converting this into a biologically active circular DNA 
strand by using the oligonucleotide to prime in vitro synthesis on a single-stranded circular 
template. This protocol (Kunkel, 1985; Messing, 1983) uses a DNA template containing a 
small number of uracil residues in place of thymine. Use of the uracil-containing template 
allows rapid and efficient recovery of mutants.  
 
2.3.3.1.  Preparation of uracil-containing, single-stranded DNA template 
CJ236 bacteria were transformed with the DNA of interest (typically pcDNA3 constructs). 2 
mL 2xYT-medium were inoculated with several colonies of transformed CJ236 at 37°C until 
the early log-phase was reached. Cultures were infected with 2x107  M13K07 phages/mL 
(Amersham) and incubated for further 1.5 h. Next, kanamycin was added (70 µg/mL final 
concentration) and the culture was incubated with vigorous shaking at 37 °C overnight. Cells 
were pelletet twice by centrifugation (13000 rpm, 5 min) to clear the supernatant. Phage was 
then precipitated by adding 200 µL 2.5 M NaCl/ 20% PEG 6000 and incubation for 15 min at 
room temperature. Precipitated phage was collected by centrifugation. The phage sediment 
was resuspended in 100 µL TE10/0.1 buffer and subjected to phenol extraction/ ethanol 
precipitation in order to purify the single-stranded phage DNA. Quality and concentration of 
DNA was determined spectrophotometrically at 260 nm. For visual examination and 
documentation an aliquot of the single-stranded DNA was run on a 1% agarose gel. 2. Materials and Methods    27 
2.3.3.2. Primer  extension 
The uracil-containing DNA was used as a template in oligonucleotide-directed mutagenesis 
experiments: 200 ng single-stranded template DNA, 2-3 pmol phosphorylated 
oligonucleotide, 1 µL 10x hybridization buffer (20 mM Tris/HCl pH 7,4, 2 mM MgCl2, 50 
mM NaCl) in a total volume of 10 µL were incubated for 2 min at 90°C and allowed to cool 
to room temperature. To the hybridization mixture 1 µL 10x synthesis buffer (5 mM 
dNTPmix, 100 mM Tris/HCl pH 7.5, 50 mM MgCl2, 20 mM DTT), 5 U T4-DNA Ligase (1 
µL), 1 µg T4-Gen 32 Protein (0.5 µL) and 3 U T4-DNA Polymerase (1 µL) were added. The 
reaction was incubated for 5 min on ice, 5 min at 25 °C and finally for 90 min at 37°C. The 
reaction was stopped by adding 66 µL TE. 100 ng of double-stranded DNA product were used 
for transformation of E. coli. Resulting clones were chosen randomLy for isolation of plasmid 
DNA which was analysed by sequencing. 
2.3.4.  Enzymatic amplification of DNA by polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is a rapid procedure for in vitro enzymatic amplification 
of a specific segment of DNA (Mullis and Faloona, 1987). A multitude of applications have 
been developed including direct cloning from cDNA, in vitro mutagenesis and engineering of 
DNA, genetic fingerprinting of forensic samples, assays for the presence of infectious agents 
and analysis of allelic sequence variations. For long and accurate cDNA amplification LATaq 
™ polymerase (TaKaRa) was used: 
 
0.5 µL template cDNA 
2 µL "sense" oligonucleotide, 10 pmol/µL 
2 µL "antisense" oligonucleotide, 10 pmol/µL 
5 µL 10x LA PCR buffer II (w/o MgCl2) 
5 µL MgCl2, 25 mM 
8 µL dNTP-Mix, 2.5 mM each 
0.5 µL LA-Taq™ (5 U/µL) 
ad 50 µL H2O 
 
PCR reactions were performed in a automated thermal cycler („Progene“, Techne). The 
following standard protocol was adjusted to the specific application:  
 
first  denaturation:      3  min  94°C 
amplification 25-30 cycles:     1 min 94°C (denaturation) 
1 min 58°C (hybridization) 
1 min/ kb product 72°C (extension) 
last  extension:     7  min  72°C 
 
10 µL from each reaction were electrophoresed on an agarose gel appropriate for the PCR 
product size expected. PCR products were subjected to isolation using the PCR purification 
kit (Qiagen). 
2.3.5. DNA  sequencing 
DNA sequencing was performed according to the “Big Dye Terminator Cycle Sequencing 
Protocol” (ABI). The following mix was subjected to a sequencing-PCR run: 
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0.5 µg DNA of interest 
10 pmol oligonucleotide 
4 µL Terminator Ready Reaction Mix 
ad 20 µL H2O 
25 cycles: 30 sec 94°C 
15 sec 45-60°C 
4 min 60°C 
 
The sequencing products were purified by sodium acetate/ EtOH precipitation, dissolved in 20 
µL template suppression reagent, denatured for 2 min at 90°C and analyzed on a 310-Genetic 
Analyzer (ABI Prism). 
2.3.6.  cDNA array hybridization 
Filters spottet with genes of interest (cloned into pBluescript SKII+) were a gernerous gift 
from J. Ruhe, cDNA probes of the cell lines Cos-7 and NCI-H292 were generated according 
to standard molecular biology methods. Labeling of 3–  5 µL of cDNA was performed with 
the Megaprime kit (Amersham) in the presence of 50 µCi of [α-
32P]dATP. The 
prehybridization solution was replaced from filters by the hybridization solution containing 5x 
SSC, 0.5% (v/v) SDS, 100 µg/mL baker yeast tRNA (Roche), and the labeled cDNA probe 
(2–5 x 106 cpm/mL) and incubated at 68°C for 16 h. Filters were washed under stringent 
conditions. A phosphorimager system (Fuji BAS 1000; Fuji) was used to quantify the 
hybridization signals. Average values for each slot were calculated using the formula: A = 
(AB  -  B)  x  100/B; [A, final volume; AB, intensity of each slot signal (pixel/mm2);  B, 
background (pixel/mm2)]. 
2.3.7. RT-PCR  analysis 
Specific silencing of targeted genes was confirmed by RT-PCR analysis. RNA isolated using 
RNeasy Mini Kit (Qiagen, Hilden, Germany) was reverse transcribed using AMV Reverse 
Transcriptase (Roche, Mannheim, Germany). PuReTaq Ready-To-Go PCR Beads (Amersham 
Biosciences, Piscataway, NJ) were used for PCR amplification. Primers (Sigma Ark, 
Steinheim, Germany) were ADAM9, 5'-AGT GCA GAG GAC TTT GAG AA-3´ and 5'-TGC 
CGT TGT AGC AAT AGG CT-3´, ADAM10, 5'-TTG CTC ACG AAG TTG GAC AT-3' 
and 5'-TTT CCC AGG TTT CAG TTT GC-3', ADAM15, 5'-GGC TGG CAG TGT CGT 
CCT ACC AGA GGG-3' and 5'-GGT GCA CCC AGC TGC AGT TCA GCT CAG TCC-3'. 
PCR products were subjected to electrophoresis on a 2.5% agarose gel and DNA was 
visualized by ethidium bromide staining. 
2.4.  Methods in mammalian cell culture 
2.4.1.  General cell culture techniques 
All cell lines were grown in a humidified 93% air, 7% CO2  incubator (Heraeus, B5060 
Ek/CO2) at 37°C and routinely assayed for mykoplasma contamination using a 
bisbenzimidestaining kit (Sigma). Before seeding cells were counted with a Coulter Counter 
(Coulter Electronics). HEK-293, Cos7 and HuH7 cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 2 mM L-glutamine, 1.0 mM sodium pyruvate 
and 10% FCS. TCC-Sup were cultured in DMEM supplemented with 2 mM L-glutamine, 1.0 
mM sodium pyruvate and 15% FCS. NCI-H292 and DAN-G cells were maintained in RPMI 
medium supplemented with 2 mM L-glutamine and 10% FCS.  2. Materials and Methods    29 
2.4.2.  Transfection of cultured cell lines 
2.4.2.1.  Transfection of cells with calcium phosphate 
HEK-293 cells in six-well dishes were transfected transiently at about 70% confluency with a 
total of 2 µg DNA by using a modified calcium phosphate precipitation method as described 
previously (Chen and Okayama, 1987). In this protocol, a calcium phosphate-DNA complex 
is formed gradually in the medium during incubation with cells. The transfection mix of DNA 
and CaCl2 in water was prepared as follows: 
 
dish       6-well      6  cm      10  cm    
area       10  cm2     21 cm2     57 cm2 
Volume of medium     1 mL       2 mL       4 mL 
DNA in H2Obidest     2 µg in 90 µL    5 µg in 180 µL   10 µg in 360 µL 
2.5 M CaCl2       10 µL      20 µL      40 µL 
2 x BBS (pH 6.96)     100 µL     200 µL     400 µL 
Total volume      200 µL     400 µL     800 µL 
 
To initiate the precipitation reaction the adequate volume of 2x BBS was added and mixed by 
vortexing. The reaction was incubated for 10 min at room temperature before being added to 
each well. Plates were placed in a humidified container at 3% CO2  overnight. One day 
following transfection, cells were serum-starved for 24 hours in standard cell culture medium 
without FCS.  
2.4.2.2.  Transfection of COS-7 cells using lipofectamine® 
COS-7 cells were transiently transfected using Lipofectamine® (Gibco-BRL) essentially as 
described (Daub et al., 1997). For transfections in 6-well dishes, 1.0 mL of serum-free 
medium containing 10 µL of Lipofectamine and 1.5 µg of total plasmid DNA per well were 
used. After 4 h the transfection mixture was supplemented with an equal volume of medium 
containing 20% FCS and, 20 h later, cells were washed and cultured for a further 24 h in 
serum-free medium until lysis. 
2.4.2.3. RNA  interference 
Transfection of 21-nucleotide siRNA duplexes (Dharmacon Research, Lafayette, CO, USA) 
for targeting endogenous genes was carried out using Oligofectamine (Invitrogen) for NCI-
H292 cells and 4.2 µg siRNA duplex per 6-well plate as previously described (Elbashir et al., 
2001). Cos-7 cells were transfected using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer's protocol. Briefly, 8.4 µg siRNA duplex per 6 cm dish were incubated with 10 
µL Lipofectamine 2000 in 1 mL serum-free medium for 20 minutes. The transfection mixture 
was added to the cell culture medium containing serum and, after 6 h, cells were washed and 
incubated in medium containing serum overnight. 
NCI-H292 and Cos-7 cells were serum-starved and assayed 2 d after transfection. Highest 
efficiencies in silencing target genes were obtained by using mixtures of siRNA duplexes 
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2.4.2.4. Apoptosis  Assay 
TCC-Sup bladder carcinoma cells were seeded in 6-well plates, grown for 20 h and treated with 10 
µM doxorubicin and CRM197 as indicated for 72 h. Cells were collected by trypsinization, 
resuspended in assay buffer containing  propidium iodide (PI), and incubated at 4° C for 3 h. Nuclear 
DNA staining was analysed on a Becton Dickinson FACScalibur flow cytometer. 
2.5.  Protein analytical methods 
2.5.1.  Lysis of cells with triton X-100 
Prior to lysis, cells grown to 80% confluence were treated with inhibitors and agonists as 
indicated in the figure legends. Cells were washed with cold PBS and then lysed for 10 min  
on ice in buffer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM 
EDTA, 10% glycerol, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 10 mM 
sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/mL aprotinin. Lysates were 
precleared by centrifugation at 13000 rpm for 10 min at 4°C. 
2.5.2. Determination  of  protein concentration in cell lysates 
The „Micro BCA Protein Assay Kit” (Pierce, Sankt Augustin) was used according to the 
manufacturers´ recommendations. 
2.5.3. Immunoprecipitation and in vitro association with fusion proteins 
An equal volume of HNTG buffer was added to the precleared cell lysates that had been 
adjusted for equal protein concentration. Proteins of interest were immunoprecipitated using 
the respective antibodies and 20 µL of protein A-Sepharose for 4 h at 4°C. Alternatively, 
lysates were subjected to in vitro associations with either 3 µg of GST-Grb2 (Daub et al., 
1997) or 2 µg of GST as control pre-bound to 30 µL of gluthathione-agarose beads. 
Precipitates were washed three times with 0.5 mL of HNTG buffer, suspended in 2× SDS 
sample buffer, boiled for 3 min, and subjected to SDS-PAGE. 
2.5.4.  TCA precipitation of proteins in conditioned medium 
Phenylmethylsulfonyl fluoride (1 mM final concentration) was added to cell culture medium 
of stimulated and control treated cells and precleared by centrifugation at 13000 rpm for 10 
min at 4°C. For TCA precipitation, proteins were incubated in 0.1 mg/mL sodium 
deoxycholate, 0.6 M TCA for 30 min on ice. 
2.5.5. SDS-polyacrylamide-gelelectrophoresis (SDS-PAGE) 
SDS-PAGE was conducted as described previously (Sambrook, 1990). The following proteins 
were used as molecular weight standards: 
 
Protein    MW  (kD)     Protein    MW  (kD) 
 
Myosin     205.0      Ovalbumin     42.7 
ß-Galaktosidase   116.25     Carboanhydrase   29.0 
Phosphorylase b   97.4       Trypsin-Inhibitor   21.5 
BSA      66.2      Lysozym  14.4 
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Because of the small size of pro-HB-EGF and the processed form of HB-EGF, the tricine 
SDS-PAGE system was used as described (Schagger and von Jagow, 1987). 
2.5.6.  Transfer of proteins on nitrocellulose membranes 
For immunoblot analysis proteins were transferred to nitrocellulose membranes (Gershoni and 
Palade, 1982) for 2 h at 0.8 mA/cm2  using a "Semidry”-Blot device in the presence of 
Transblot-SD buffer. Following transfer proteins were stained with Ponceau S (2 g/l in 2% 
TCA) in order to visualize and mark standard protein bands. The membrane was destained in 
water. 
2.5.7. Immunoblot  detection 
After electroblotting the transferred proteins are bound to the surface of the nitrocellulose 
membrane, providing access for reaction with immunodetection reagents. Remaining binding 
sites were blocked by immersing the membrane in 1x NET, 0.25% gelatin for at least 4 h. The 
membrane was then probed with primary antibody (typically overnight). Antibodies were 
diluted 1:500 to 1:2000 in NET, 0.25% gelatin. The membrane was washed 3x 20 min in 1x 
NET, 0.25% gelatin, incubated for 1 h with secondary antibody and washed again as before. 
Antibody-antigen complexes were identified using horseradish peroxidase coupled to the 
secondary anti-IgG antibody. Luminescent substrates were used to visualize peroxidase 
activity. Signals were detected with X-ray films or a digital camera unit. Membranes were 
stripped of bound antibody by shaking in strip-buffer for 1 h at 50°C. Stripped membranes 
were blocked and reproped with different primary antibody to confirm equal protein loading.  
2.5.8. Differential  detergent fractionation 
Differential detergent fractionation was carried out as described before (Ramsby et al., 1994). 
Cells were pre-treated with inhibitors as indicated in the figure legends. Following 
stimulation, cells were washed in PBS, and a cytosolic-enriched fraction was obtained using a 
digitonin buffer (0.01% digitonin, 10 mM PIPES (pH 6.8), 300 mM sucrose, 100 mM NaCl, 3 
mM MgCl2, 5 mM EDTA) and centrifugation at 480x g. The supernatant was carefully 
removed as the cytosolic-enriched fraction. The membrane-enriched fraction was obtained by 
resuspending the pellet in TritonX 100 buffer (0,5% Triton X100, 10 mM PIPES (pH 7.4), 
300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 3 mM EDTA), centrifugation at 5000x g for 
10 min and careful removal of the supernatant. The pellet obtained was were resuspended in 
Tween40/DOC buffer (1% Tween 40, 0.5% deoxycholate, 10 mM PIPES (pH7.4), 10 mM 
NaCl, 1mM MgCl2). To break up nuclei, 20 strokes in a Dounce homogenizer were applied 
followed by ultrasonication and centrifugation at 6780x g. The supernatant was collected as 
the nuclei-enriched fraction. Protein concentration was determined using the BCA protein 
assay kit (Pierce), and equal amounts of protein were subjected to gel electrophoresis and 
western blotting. 
 
2.6.  Biochemical and cell biological assays 
2.6.1.  Stimulation of cells 
Cells were seeded in cell culture dishes of appropriate size and grown overnight to about 80% 
confluence. After serum-starvation for 48 h HNSCC cells were treated with inhibitors and 
agonists as indicated in the figure legends, washed with cold PBS and then lysed for 10 min 2. Materials and Methods    32 
on ice. In some cases cells were transfected 24 h after seeding and serum-starved one day 
following transfection before being stimulated as indicated above. 
2.6.2. ERK1/2  phosphorylation 
For determination of ERK1/2 and Akt phosphorylation, approximately 20 µg of whole cell 
lysate protein/lane was resolved by SDS-PAGE and immunoblotted using rabbit polyclonal 
phospho-specific ERK/MAPK antibody. Akt phosphorylation was detected by protein 
immunoblotting using rabbit polyclonal anti-phospho-Akt antibody. Quantitation of ERK1/2 
was performed using the Luminescent Image Analyis System (Fuji). After quantitation of 
ERK1/2 phosphorylation, membranes were stripped of immunoglobulin and reprobed using 
rabbit polyclonal anti-ERK1/2 or rabbit polyclonal anti-Akt antibody to confirm equal protein 
loading. 
2.6.3. ERK/MAPK  activity 
HA-ERK2 or endogenous ERK2 were immunoprecipitated from lysates obtained from 
sixwell dishes using 0.5 µg of anti-HA antibody or 0.4 µg of anti-ERK2 antibody, 
respectively. Precipitates were washed three times with HNTG buffer, and washed once with 
kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 200 µM sodium 
orthovanadate). Kinase reactions were performed in 30 µL of kinase buffer supplemented  
with 0.5 mg/mL myelin basic protein, 50 µM ATP and 1 µCi of [γ-32P]ATP for 10 min at 
room temperature. Reactions were stopped by addition of 30 µL of LaemmLi buffer and 
subjected to gel electrophoresis on 15% gels. Labeled MBP was quantitated using a 
Phosphoimager (Fuji). 
2.6.4.  JNK activity assay 
JNK activity was assayed as described previously (Sudo and Karin, 2000). Cultured cells 
were lysed in lysis buffer containing 20 mM Tris (pH7.6), 0.5% Nonidet P-40, 250 mM NaCl, 
3 mM EDTA, 1 mM dithiotreitol, 0.5 mM phenylmethylsulfonylfluoride, 20 mM β-
gylcerophosphate, 1 mM sodium orthovanadate and 1µg/mL leupeptin. JNK was 
immunoprecipitated from lysates obtained from 6-well dishes using polyclonal anti-JNK 
antibody. Immunoprecipitates were washed twice using lysis buffer  and twice using kinase 
assay buffer (25 mM HEPES (pH 7.5), 20 mM β-gylcerophosphate, 20 mM PNPP, 20 mM 
MgCl2, 2 mM dithiotreitol and 0.1 mM sodium orthovanadate). Kinase reactions were 
performed in 30 µL of kinase buffer supplemented with 1 µg GST-c-Jun (aa1-79), 20 µM 
cold ATP and 5 µCi of [γ-
32P]ATP at 30° C for 30 minutes. Reactions were stopped by 
addition of 30 µL of Laemmli buffer and subjected to gel electrophoresis on 12.5% gels. 
Labeled GST-c-Jun was quantitated using a Phosphoimager (Fuji). 
2.6.5.  Flow cytometric analysis of cell surface proteins 
Was performed as described before (Prenzel et al., 1999). In brief, cells were seeded, grown 
for 20 h and in some cases retrovirally infected as indicated. Upon serum-starvation for 24 h 
cells were treated with inhibitors and growth factors as indicated. After collection, cells were 
stained with ectodomain-specific antibodies against HB-EGF, TGFα or AR for 45 min. After 
washing with PBS, cells were incubated with FITC-conjugated secondary antibodies for 15 
min and washed again with PBS. Cells were analysed on a Becton Dickinson FACScalibur 
flow cytometer. 2. Materials and Methods    33 
2.6.6.  Detection of ROS by flow cytometric analysis 
Cells were seeded in 6-well dishes and grown for 48 hrs. Prior to stimulation cells were 
preincubated with 20 µM DCF-DA for 30 min and subsequently stimulated as indicated for 
15 min. After trypsinization, cells were centrifuged at 800x g and resuspended in PBS with 
propidium iodide. Cells were immediately analyzed on a Becton Dickinson FACScalibur flow 
cytometer. 
2.6.7. Incorporation  of 
3H-thymidine into DNA 
SCC-9 or SCC-25 cells were seeded into 12-well plates (2.5 x 104 or 6 x 104 cells per well, 
respectively). Upon serum deprivation for 48 h, cells were subjected to preincubation with 
inhibitors before ligand treatment. After 18 h incubation, cells were pulse-labelled with 
3H  
thymidine (1 µCi/mL) for 4 h, and thymidine incorporation was measured by trichloroacetic 
acid precipitation and subsequent liquid-scintillation counting. 
2.7. Statistical  analysis 
Student’s t-test was used to compare data between two groups. Values are expressed as mean 
± standard deviation (s. d.) of at least triplicate samples. P < 0.05 was considered statistically 
significant. 
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3.  Results 
3.1.  EGFR Signal Transactivation in pancreatic and non-small cell lung 
carcinoma 
3.1.1. GPCR-induced  EGFR  phosphorylation in NSCLC and pancreatic 
carcinoma 
Dysregulated EGFR signalling has been associated with both non-small cell lung carcinoma 
and pancreatic carcinoma (Bardeesy and DePinho, 2002; Sridhar et al., 2003). Moreover both 
types of cancer have been linked to autocrine signalling loops involving GPCR ligands 
(Moody et al., 2003). To address the question whether the EGFR provides a convergence 
point for GPCR-induced signalling in NSCLC and pancreatic carcinoma within a 
metalloprotease-dependent EGFR signal transactivation pathway, we stimulated different cell 
lines with GPCR agonists and investigated EGFR phosphorylation depending on 
metalloprotease activity by preincubation with the metalloprotease inhibitor batimastat 
(BB94). As shown in Figure 6 and Figure 7, GPCR stimulation induces metalloprotease-
dependent phosphorylation of the EGFR in both NSCLC and pancreatic carcinoma cell lines.  
 
Figure 6 EGFR signal transactivation in pancreatic carcinoma cell lines. Following serum starvation for 24 
hrs,  DAN-G and BxPc-3 cells were incubated with 5 µM BB94 for 20 min and subsequently stimulated with 
GPCR agonists as indicated. EGFR was immunoprecipitated from cell lysates, transferred to nitrocellulose and 
immunoblot against phosphotyrosine was performed. The same membranes were stripped and reprobed for total 
EGFR content. 
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Figure 7 Different GPCR ligands induce metalloprotease-dependent EGFR phosphorylation in NSCLC 
cell lines. A549, Calu-6 and NCI-H292 cells were serum-starved for 24 hrs. Prior to stimulation, cells were 
preincubated with the metalloprotease inhibitor batimastat (BB94, 5 µM) for 20 min and stimulated as indicated. 
EGFR phosphorylation was assessed by immunoprecipitation followed by immunoblot analysis.  
 
3.1.2.  EGFR signal transactivation-induced downstream signalling 
The finding that GPCR ligands induce metalloprotease-dependent EGFR signal 
transactivation in these cell lines raised the question whether EGFR characteristic downstream 
signalling dependent on this signalling mechanism could be observed. The adaptor protein 
Shc represents a prominent downstream signalling partner of the EGFR which becomes 
tyrosine phosphorylated in response to EGFR stimulation.  
Figure 8 demonstrates that stimulation of A549 NSCLC cells with LPA and bradykinin (BK) 
induces metalloprotease-dependent Shc phosphorylation, while Thrombin (Thr) or Carbachol 
(Car) phosphorylate Shc only weakly. In contrast, Gastrin-releasing peptide induced Shc 
phosphorylation is independent of metalloprotease activity. 
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Figure 8 GPCR-induced Shc phosphorylation depends on metalloprotease activity in A549 cells. A549 were 
serum-starved for 24 hrs, preincubated with BB94 (5 µM, 20 min) and stimulated as indicated in the figure. Shc 
was immunoprecipitated from total cell lysates and samples were run on SDS-PAGE. Following transfer to 
nitrocellulose membrane the filter was probed for total Shc protein, stripped and reprobed for phosphotyrosine 
content. 
 
The MAPKs ERK1/2 comprise the so far best characterized EGFR downstream signalling 
pathway. Moreover, they have been linked to important cellular responses such as cell 
proliferation, differentiation or anti-apoptosis (Chang and Karin, 2001; Johnson and Lapadat, 
2002). Therefore we used phosphospecific antibodies  to assess the phosphorylation state of 
the MAPKs ERK1 and ERK2 in A549, DAN-G and BxPc-3 cells. Interestingly, in the 
NSCLC cell line A549 GPCR agonist treatment induces MAPK phosphorylation but in a 
metalloprotease- and therefore EGFR signal transactivation-independent manner (Figure 9). A 
similar result was obtained in the pancreatic carcinoma cell line DAN-G (Figure 9). In 
contrast, in the pancreatic carcinoma cell line BxPc-3 endothelin-1 and bradykinin stimulate 
ERK1/2 phosphorylation in a metalloprotease-dependent fashion. 3. Results    37 
 
 
Figure 9 ERK1/2 phosphorylation in response to GPCR agonist treatment dependent on metalloprotease 
activity. A549, DAN-G and BxPc-3 cells were serum-starved for 24 hrs, incubated with BB94 (5 µM, 20min) 
and stimulated as indicated for 3 min. Total cell lysates were subjected to SDS-PAGE, transferred to 
nitrocellulose and immunoblot analysis against phospho-ERK1/2 was performed. The same filters were reprobed 
for total ERK1/2 content. 
 
Moreover, as shown in Figure 10, metalloprotease- and EGFR-dependent ERK2 activation in 
response to both LPA and bradykinin treatment could be observed in the NSCLC carcinoma 
cell line NCI-H292 using an ERK2 kinase assay. While bradykinin stimulation was 
completely abolished by both the metalloprotease inhibitor BB94 and the selective EGFR 
kinase inhibitor AG1478, LPA-induced ERK2 activation was only blocked by 50% by 
metalloprotease inhibition (Figure 10). 3. Results    38 
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Figure 10 MAPK activity assay of ERK2 in NCI-H292 cells in response to LPA stimulation. NCI-H292 cells 
were serum-starved for 24 hrs, incubated with AG1478 (250 nM, 20 min), BB94 (5 µM, 20 min) or an equal 
volume DMSO (20 min) and stimulated with LPA (10 µM, 10 min), BK (2 µM, 10 min) or EGF (2 ng/mL, 10 
min). ERK2 was immunoprecipitated and a radioactive kinase assay performed as described under materials and 
methods. Quantitative analysis of ERK phosphorylation from three independent experiments (mean ± s.d.) using 
the FUJI LAS1000 imaging system.  
3.1.3.  LPA stimulation induces DNA synthesis in NCI-H292 cells 
Having established a role for metalloprotease-dependent EGFR signal transactivation in 
ERK1/2 activation depending on the cellular system and the stimulus, we addressed the 
question whether this GPCR-stimulated signal is able to induce cell proliferation. We used the 
thymidine incorporation assay to assess the DNA synthesis rate in NCI-H292 cells in response 
to LPA treatment, depending on both metalloprotease and EGFR function, since this cell line 
showed the strongest response to GPCR agonist treatment on both the EGFR and ERK level 
(Figure 7,Figure 10). As shown in Figure 11, LPA stimulation induces a 2,3 fold induction of 
DNA-synthesis, which is comparable to treatment with 2 ng/mL EGF. While metalloprotease 
inhibition blocked MAPK activity only to 50%, BB94 is able to reduce the LPA stimulated 
thymidine incorporation to basal levels. The same result was obtained using the EGFR 
inhibitor AG1478 (Figure 11).  3. Results    39 
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Figure 11 Metalloprotease-dependent EGFR signal transactivation mediates LPA-induced DNA-synthesis 
in NCI-H292 cells. NCI-H292 were seeded in 12-well plates (2*10
4 per well) and serum-starved for 24 hrs. 
Following preincubation with AG1478 (250 nM, 20 min) or BB94 (5 µM, 20 min) cells were stimulated over 
night with LPA (10 µM) or EGF (2 ng/mL). The following day thymidine incorporation assays was performed as 
described under materials and methods. Data shown are representative for three independent experiments (mean 
± S.D.). 
 
3.2.  Stress signalling in human tumour cells is mediated by HB-EGF and 
ADAM proteases 
3.2.1. Distinct kinetics of EGFR and MAPK activation in Cos-7 and human 
carcinoma cell lines  
Previous investigations attributed heterogeneous EGFR activation mechanisms, i.e. activation 
of the EGFR by stimuli other than EGF-like ligands such as GPCR agonists or non-
physiologic stress stimuli, to completely ligand-independent and therefore intracellular 
pathways (Daub et al., 1996; Knebel et al., 1996). However, recent results demonstrated the 
involvement of EGF-like ligands in EGFR activation by GPCR agonists (Prenzel et al., 1999). 
This finding lead us to investigate whether cellular stress stimuli such as osmotic and 
oxidative stress, which both induce tyrosine phosphorylation of the EGFR and activation of 
MAPKs in a wide variety of cell systems (Carpenter, 2000; de Nadal et al., 2002; King et al., 
1989), utilize a ligand-dependent mechanism to activate the EGFR. To elucidate the 
underlying mechanisms, we performed time course experiments in Cos-7 and TCC-Sup 
bladder carcinoma cell lines and analysed EGFR phosphorylation with phosphotyrosine-
specific and MAPK phosphorylation with activation-specific antibodies by immunoblot 
analysis. As shown in the upper panels of Figure 12, tyrosine phosphorylation of the EGFR in 
response to the stress agents sorbitol (0.3 M) and hydrogen peroxide (200 µM) occurred in 3. Results    40 
 
both cell lines within 5 to 10 min and thus preceded the activation of ERK and JNK MAPKs, 
which became phosphorylated after 10 and 15 min, respectively (Figure 12 A/B, lower panel). 
In contrast, phosphorylation of p38 occurred as an immediate response to stress agents. The 
results of these time course experiments were consistent with a role of p38 as upstream 
mediator of EGFR activation and further pointed to a function of ERK1/2 and JNK as 
downstream effectors of the EGFR in response to stress stimuli. 
 
 
Figure 12 Time-course of stress-induced EGFR and MAPK phosphorylation in different cell lines. (A) 
EGFR and MAPK phosphorylation in response to osmotic and oxidative stress. Cos-7 cells were treated 
with sorbitol (0.3 M) and hydrogen peroxide (200 µM) for the indicated time periods. Following 
immunoprecipitation (IP) of cell extracts with anti-EGFR antibody proteins were immunoblotted (IB) with anti-
phosphotyrosine antibody and re-probed with anti-EGFR antibody. Phosphorylated MAPKs were detected by 
immunoblotting total lysates with anti-phospho-ERK, anti-phospho-JNK and anti-phospho-p38 antibody. The 
same filters were re-probed with anti-p38 antibody. (B) Stress-induced EGFR phosphorylation in human bladder 
carcinoma cell lines. TCC-Sup cells were treated as indicated in (A). 
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3.2.2.  Stress-induced EGFR activation is independent of Src activity 
Chen  et al. reported hydrogen peroxide-induced activation of the EGFR in a ligand-
independent manner in Cos-7 cells by activation of the non-receptor tyrosine kinase c-Src, 
which in turn phosphorylates the EGFR (Chen et al., 2001a). To test whether this ligand-
independent mechanism accounts for both oxidative and osmotic stress-induced EGFR 
phosphorylation in Cos-7 cells we employed the same experimental setup using the Src 
specific inhibitor PP2 as described by Chen et al. Figure 13 shows a concentration course of 
the Src inhibitor and its effect on EGFR phosphorylation induced by EGF. A PP2 
concentration of 10 µM as used by Chen et al. inhibited EGFR kinase function unspecifically 
(Figure 13, upper panel). When PP2 was used at a concentration that did not affect EGFR 
kinase activity no inhibition of stress-induced EGFR phosphorylation could be observed, 
suggesting that Src is not involved in EGFR activation in response to osmotic or oxidative 
stress in Cos-7 cells. 
 
Figure 13 Stress-induced EGFR activation is independent of Src activity. Serum-starved Cos-7 cells were 
preincubated with PP2 for 30 min at the indicated concentrations. After stimulation with sorbitol (0.3 M, 10 
min), H2O2 (200 µM, 10 min) or EGF (2 ng/mL, 3 min) EGFR was immunoprecipitated and immunoblot 
analysis was performed to assess its phosphorylation state. The same filters were stripped and reprobed for 
EGFR content. 
3.2.3. Redox-dependent activation of Gαi/o is not involved in stress-induced 
EGFR activation 
Nishida and colleagues reported the activation of Gα subunits of the Gαi/o family in response 
to treatment with hydrogen peroxide by oxidation of a cysteine residue characteristic for these 
Gα protein subtype (Nishida et al., 2000). Since these G protein subunits have been 3. Results    42 
 
implicated in EGFR signal transactivation (Daub et al., 1997), we investigated whether this 
direct G protein activation mechanism independent of GPCR stimulation is involved in 
oxidative and osmotic stress-induced EGFR activation. As shown in Figure 14, preincubation 
of Cos-7 cells with the bacterial pertussis toxin (PTX), which modifies and inactivates Gαi/o 
subunits by ADP-ribosylation (Schiavo and van der Goot, 2001), had no effect on sorbitol- or 
hydrogen peroxide-induced EGFR activation. In contrast, LPA-stimulated EGFR signal 
transactivation serving as a positive control was blocked to 50%, as reported by Daub and 
colleagues (Daub et al., 1997). 
 
Figure 14 Pertussis toxin-sensitive Gα subunits are not involved in stress-induced EGFR activation. Cos-7 
cells were seeded, serum-starved for 24 hrs and at the same time incubated with pertussis toxin 18 hrs prior to 
stimulation. After 24 hours of serum starvation cells were stimulated with 0.5 M sorbitol and 200 µM hydrogen 
peroxide for 10 min and 10 µM LPA for 3 min. Cells were lysed and assessed for EGFR phosphorylation content 
as described under Figure 12. 
3.2.4.  p38 controls EGFR activation by osmotic and oxidative stress 
The finding that p38 activation preceded EGFR tyrosine phosphorylation (Figure 12) raised 
the question whether p38 acts as an upstream regulator of EGFR stimulation in Cos-7 and 
human carcinoma cell lines. Preincubation of Cos-7 cells with the selective EGFR-kinase 
inhibitor AG1478 did not affect p38 phosphorylation in response to stress agents (Figure 15), 
demonstrating that p38 activation was independent of EGFR activity.  
 
 
Figure 15 Time-course of p38 phosphorylation dependent on EGFR kinase function. Cos-7 cells were 
pretreated with AG1478 (250 nM) or an equal volume of empty vehicle (DMSO) for 20 min and stimulated with 
0.3 M sorbitol or 200 µM hydrogen peroxide for the indicated periods. Cell extracts were immunoblotted with 
anti-phospho-p38 antibody and reprobing of the same filters with polyclonal anti-p38 antibody. 3. Results    43 
 
 
To address the question whether p38 is located upstream of the EGFR, we used the p38-
specific inhibitor SB202190 to investigate the effect of blocking p38 activity on stress-
induced EGFR activation. As shown in Figure 16A, preincubation of Cos-7 cells with 
SB202190 completely abrogated stress-induced EGFR activation while leaving 
lysophosphatidic acid (LPA) and EGF-induced tyrosine phosphorylation unaffected. In 
contrast, the MEK1/2 inhibitor PD98059 did not affect EGFR phosphorylation. Analogous 
results were obtained with the bladder carcinoma cell line TCC-Sup (Figure 16B). Taken 
together, these results implicate p38 as an upstream mediator of EGFR activation in the stress-
induced signalling response of  Cos-7 and TCC-Sup bladder carcinoma cells. 
 
 
 
Figure 16 Stress-induced EGFR activation depends on p38 but not on ERK activity in Cos-7 and TCC-Sup 
bladder carcinoma cells. (A) Cos-7 cells were pre-treated with PD98059 (50 µM), SB202190 (10 µM) or an 
equal volume of empty vehicle (DMSO) for 30 min and stimulated with 0.3 M sorbitol and 200 µM hydrogen 
peroxide for 10 min and the GPCR agonist LPA (10 µM) or EGF (2 ng/mL) for 3 min as positive controls. Cell 
extracts were assayed for EGFR tyrosine phosphorylation content. (B) Stress-induced EGFR activation depends 
on p38 activity in TCC-Sup carcinoma cells. TCC-Sup cells were pre-treated as described under (A) and 
stimulated with 0.3 M sorbitol and 200 µM hydrogen peroxide for 10 min and EGF (2 ng/mL) for 3 min as a 
positive control. After lysis cell extracts were assayed for EGFR tyrosine phosphorylation content. 3. Results    44 
 
3.2.5.  Stress-induced EGFR phosphorylation depends on metalloprotease activity 
and HB-EGF function 
Recent investigations underscored the importance of EGF-like ligand precursor processing in 
EGFR phosphorylation upon stimuli such as GPCR signals (Zwick et al., 1999). Based on 
these findings, we asked whether EGFR activation by stress stimuli may also involve a 
ligand-dependent mechanism. We therefore preincubated cells with the metalloprotease 
inhibitor batimastat (BB94), which has been shown to inhibit EGF-like ligand processing and 
subsequent EGFR transactivation (Zwick et al., 1999). Upon stimulation with stress agents, 
EGFR tyrosine phosphorylation was monitored by immunoblot analysis with 
phosphotyrosine-specific antibody. As shown in Figure 17, BB94 almost completely blocked 
sorbitol or hydrogen peroxide-induced EGFR phosphorylation in Cos-7 and TCC-Sup bladder 
carcinoma cells (upper and middle panel). In the lung carcinoma cell line NCI-H292, BB94 
reduced EGFR activation by about 50%, suggesting an alternative parallel activation 
mechanism (Figure 17, lower panel). Next, we investigated the effect of the diphtheria toxin 
mutant CRM197 which specifically abolishes HB-EGF function, on stress-activated EGFR 
tyrosine phosphorylation. Indeed, CRM197 inhibited EGFR phosphorylation to the same 
extent as BB94, suggesting that HB-EGF is critically involved in stress-induced EGFR 
activation in the three cell lines tested. Control stimulations showed that EGFR tyrosine 
phosphorylation by LPA was completely prevented by both inhibitors while neither CRM197 
nor BB94 affected direct receptor stimulation upon EGF treatment.  3. Results    45 
 
 
Figure 17 EGFR activation in response to osmotic and oxidative stress depends on metalloprotease-
mediated HB-EGF processing. (A)  Effect of metalloprotease and HB-EGF inhibition on EGFR 
phosphorylation. Cos-7, NCI-H292 and TCC-Sup cells were serum-starved for 24 hrs, pre-treated with BB94 (10 
µM), the diphtheria toxin mutant CRM197 (10 µg/mL) or an equal volume of empty vehicle (DMSO) for 20 
min, and stimulated for 10 min with 0.3 M sorbitol, 200 µM hydrogen peroxide, 10 µM LPA or 2 ng/mL EGF. 
Following immunoprecipitation of cell extracts with anti-EGFR antibody proteins were immunoblotted with 
anti-phosphotyrosine antibody and re-probed with anti-EGFR antibody. 
 
Furthermore, we investigated whether this ligand-dependency is also observed at the EGFR 
substrate level. Shc adaptor proteins are well-characterised adaptor proteins linking the EGFR 
to activation of the Ras/Raf/ERK-MAPK signalling cascade. As shown in Figure 18, both 
CRM197 and BB94 pre-treatment of Cos-7 cells strongly suppressed SHC tyrosine 
phosphorylation in response to stress stimuli resembling that of the EGFR itself. Therefore, 
phosphorylation of Shc by stress stimuli critically depends on a ligand-dependent EGFR 
phosphorylation mechanism in Cos-7 cells. 3. Results    46 
 
 
 
Figure 18 Analysis of Shc phosphorylation in response to stress agents. Cos-7 cells were treated as described 
under Figure 17. After immunoprecipitation of Shc from cell extracts with a polyclonal anti-Shc antibody 
proteins were immunoblotted with anti-phosphotyrosine antibody and re-probed with anti-Shc antibody. 
3.2.6.  Ectodomain shedding of proHB-EGF is induced in response to osmotic and 
oxidative stress in Cos-7 cells 
To further substantiate the role of HB-EGF in this ligand-dependent EGFR stimulation 
mechanism, we directly investigated proHB-EGF processing by flow cytometric analysis of 
the total amount of ligand precursor present on the cell surface of Cos-7 cells prior to and 
after stimulation with sorbitol or hydrogen peroxide. As shown in Figure 19, both stimuli lead 
to a significant decrease of  HB-EGF precursor detectable on the cell surface. Moreover, in 
accordance with the results presented in Figure 17, pre-treatment with the metalloprotease 
inhibitor BB94 abolished proHB-EGF processing.  
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Figure 19 Flow cytometric analysis of proHB-EGF processing in response to stress agents. Cos-7 cells were 
pre-treated with BB94 (10 µM) or an equal volume of empty vehicle (DMSO) for 20 min, and stimulated with 
0.3 M sorbitol or 200 µM hydrogen peroxide for 30 min. Cells were collected and stained for surface proHB-
EGF and analyzed by flow cytometry. 
 
In addition to the reduction of HB-EGF precursor, we used Cos-7 cells ectopically expressing 
proHB-EGF to determine the amount of mature soluble HB-EGF released from the cell 
surface into the supernatant. As shown in Figure 20, both treatment with sorbitol or hydrogen 
peroxide induced an increase of mature HB-EGF in the cell culture supernatant as determined 
by immunoblot analysis. Again, HB-EGF release was blocked by preincubation with the 
metalloprotease inhibitor BB94 confirming the involvement of a metalloprotease. 
 
 
Figure 20 Immunoblot analysis of conditioned media. Cos-7 cells were transiently transfected with proHB-
EGF cDNA. After serum starvation for 24 hours cells were stimulated for 20 minutes with sorbitol (0.3 M) or 
hydrogen peroxide (200 µM), and proteins within the supernatant were precipitated using trichloroacetic acid 
(TCA) precipitation. Precipitated proteins were subjected to tricin-sodiumdodecylsulfate gel electrophoresis 3. Results    48 
 
following the protocol of Schägger-Jagow and subsequent immunoblot analysis with anti-HB-EGF antibody. 
TPA stimulation has been included as a positive control. 
 
3.2.7.  Metalloproteases of the ADAM family mediate EGFR activation by 
osmotic and oxidative stress 
The finding that metalloprotease-dependent mechanisms significantly contribute to stress-
induced EGFR and Shc activation raised the question which metalloprotease(s) are involved 
in this signalling cascade. cDNA microarray analysis of NCI-H292 cells revealed that those 
ADAM family proteases which have already been implicated in EGF-like ligand cleavage are 
expressed in this cell line (Asakura et al., 2002; Izumi et al., 1998; Peschon et al., 1998; 
Sunnarborg et al., 2002; Yan et al., 2002) (Figure 12). In Cos-7 cells cDNA microarray 
analysis revealed expression of ADAM9, 10, 15 and 17 and of the EGF-like ligands HB-EGF, 
EGF and TGF-α (Stefan Hart, this group, personal communication). 
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Figure 21 cDNA micro-array analysis of NCI-H292 cells for ADAM expression and EGF-like ligand . 
Expression analysis was performed as described in the section materials and methods. 
 
We used the RNA interference technique to inhibit the endogenous expression of the 
proteases ADAM9, -10, -12, -15 and ADAM17. Figure 22 shows the efficient and specific 
knockdown of target gene expression by the siRNAs against ADAM9, 10 and 15 using RT-
PCR analysis. The siRNAs against ADAM12 and 17 have been described previously 
(Gschwind et al., 2003). Transient transfection of these siRNAs directed against the individual 
proteases and subsequent phosphotyrosine analysis of the EGFR upon stimulation with either 
sorbitol or hydrogen peroxide revealed that ADAM10 and ADAM17 are involved in EGFR 
activation in response to both stress stimuli in Cos-7 cells (Figure 23 A). Since we were 
particularly interested in the regulation of these processes in human cancer cells, we further 
investigated the involvement of ADAM family members in the lung carcinoma cell line NCI-3. Results    49 
 
H292. Similar to the results obtained in Cos-7 cells, ADAM17 also mediates the stress-
induced EGFR activation as demonstrated in Figure 23 B. But, in contrast to Cos-7 cells, 
ADAM9 and not ADAM10 is involved in the stress response of NCI-H292 cells. Thus, cell-
type specific but overlapping sets of ADAM family members regulates HB-EGF-dependent 
EGFR activation in response to stress agents.  
 
 
Figure 22 Blockade of ADAM metalloprotease expression by RNA interference (RNAi). NCI-H292 cells 
were transfected with siRNA against ADAM9, ADAM10 or ADAM15, cultured for 2 days and analyzed  for 
gene expression by RT-PCR as indicated.  
 
 
Figure 23 RNAi-induced downregulation of ADAM metalloproteases interferes with stress-induced EGFR 
activation. (A) Cos-7 cells were transfected with siRNAs against ADAM9, -10, -12, -15 and –17, serum-starved 
for 24 hours, stimulated with 0.3 M sorbitol or 200 µM hydrogen peroxide for 10 min and assayed for EGFR 
tyrosine phosphorylation content. (B) NCI-H292 cells were treated as described under (A). 3. Results    50 
 
 
3.2.8.  Activation of the MAPKs ERK1/2 and JNK in response to hyperosmolarity 
and oxidative stress is mediated by HB-EGF-dependent EGFR activation 
Since the MAPKs ERK1/2 and JNK are activated by hypertonicity and reactive oxygen 
species (de Nadal et al., 2002; Kyriakis and Avruch, 2001), we asked whether the ligand-
dependent EGFR phosphorylation contributes to the induction of these MAPK family 
members by stress stimuli. To investigate the overall dependence of stress-induced MAPK 
activation on the EGFR kinase activity, we used the selective EGFR inhibitor AG1478. 
Furthermore, we compared the effect of tyrosine kinase inhibition with the suppression of  
ligand-dependent EGFR activation by BB94 and CRM197. As shown in Figure 24 (upper 
panel), both sorbitol and hydrogen peroxide-induced activation of ERK1/2 is blocked by 
AG1478. Moreover, BB94 and CRM197 are almost as effective in blocking ERK1/2 
phosphorylation. These data suggest that stress-induced ERK1/2 activation in Cos-7 cells 
almost completely depends on EGFR activation, which can be largely attributed to a ligand-
dependent mechanism.  
The same experimental setup was used to address the question whether the same mechanistic 
concept is valid for stress signalling in human carcinoma cell lines. As shown in Figure 6A, 
we found that hyperosmolarity- and oxidative stress-induced ERK1/2 activation in TCC-Sup 
and NCI-H292 cells was substantially blocked by AG1478, BB94 or CRM197 (Fig. 6A, 
middle and lower panel). Interestingly, although oxidative stress induces EGFR 
phosphorylation only partially through a ligand-dependent mechanism in NCI-H292 cells, 
ERK activation depends mainly on proHB-EGF processing in this cell type.  3. Results    51 
 
 
Figure 24 ERK1/2 activation in response to stress agents and blockade of EGFR, metalloprotease and HB-
EGF function. Cos-7 cells transiently transfected with pcDNA3-HA-ERK2, TCC-Sup and NCI-H292 cells were 
pre-treated with AG1478 (250 nM), BB94 (10 µM), CRM197 (10 µg/mL) or an equal volume of empty vehicle 
(DMSO) for 20 min and  stimulated with 0.3 M sorbitol or 200 µM hydrogen peroxide for 30 min. After cell 
lysis total lysates were immunoblotted with anti-phospho-ERK antibody, followed by reprobing of the same 
membranes with polyclonal anti-ERK antibody. Quantitative analysis of ERK phosphorylation from three 
independent experiments (mean ± s.d.) using the FUJI LAS1000 imaging system. *P < 0.001 for control versus 
stimulation. **P < 0.006 for stimulation versus stimulation + inhibitors.  
 
In addition to ERK1/2, we were interested in the signalling mechanisms leading to activation 
of JNK MAPKs. Figure 25 (upper panel) shows the JNK activity induced by osmotic and 
oxidative stress upon pre-treatment with AG1478, BB94 or CRM197. While sorbitol-induced 
JNK activity is largely independent of the EGFR in Cos-7 cells, 50% of the oxidative stress-
induced JNK activity depend on the EGFR and HB-EGF. Similar results were obtained in the 3. Results    52 
 
bladder carcinoma cell line TCC-Sup as shown in Figure 25 (middle panel). In contrast, 
hydrogen peroxide stimulated JNK activation in the lung carcinoma cell line NCI-H292 
appears to be independent of the EGFR, while JNK activity in response to hypertonicity 
partially depends on a ligand-dependent EGFR activation pathway. 
 
 
Figure 25 JNK activation in response to stress agents and blockade of EGFR, metalloprotease and HB-
EGF function. (A) Cos-7 and NCI-H292 cell were treated as described under Figure 24. After lysis, JNK was 
immunoprecipitated using an anti-JNK antibody, and JNK activity was assayed using GST-c-JUN fusion protein 
as a substrate. Phosphorylated GST-c-JUN was visualized by autoradiography and JNK was immunoblotted in 
parallel using polyclonal JNK antibody. Quantitative analysis of GST-c-JUN phosphorylation from three 
independent experiments (mean ± s.d.) using the FUJI LAS1000 imaging system. *P < 0.001 for control versus 
stimulation. **P < 0.01 for H2O2 stimulation versus H2O2 + inhibitors. TCC-Sup cells were treated as described 
under (A). After cell lysis, JNK phosphorylation was assayed by immunoblotting cell extracts with anti-
phospho-JNK antibody and reprobing of the same filters with anti-JNK antibody.  3. Results    53 
 
 
In agreement with the finding that p38 acts as an upstream mediator of stress-induced EGFR 
activation Figure 16, p38 activity neither depended on the EGFR kinase activity nor on 
metalloprotease or HB-EGF function in Cos-7 cells (Figure 26). 
 
 
Figure 26 p38 phosphorylation is independent of EGFR, metalloprotease and HB-EGF function. Cos-7 
cells were treated as described under Figure 24. p38 phosphorylation was assayed by immunoblotting cell 
extracts with anti-phospho-p38 antibody and re-probing the same filters with anti-p38 antibody. 
3.2.9. Blockade of HB-EGF function strongly enhances doxorubicin-induced cell 
death 
Treatment of tumour cells with chemotherapeutics has been shown to activate the stress 
kinases p38 and JNK (Benhar et al., 2002b). Similar results with respect to p38 activation 
were obtained with TCC-Sup bladder carcinoma cells after exposure to the chemotherapeutic 
doxorubicin (Figure 27).  
 
 
Figure 27 p38 activation in response to doxorubicin treatment. TCC-Sup cells were seeded and treated with 
doxorubicin for the indicated time points. After cell lysis, p38 activation was assessed by immunoblotting cell 
extracts with anti-phospho-p38 antibody and reprobing of the same filters with anti-p38 antibody.   
 
In this physiological context, p38-triggered proHB-EGF processing and subsequent EGFR 
activation might provide a cellular survival signal and thereby counteract doxorubicin-
induced apoptosis. To test this hypothesis, we treated TCC-Sup cells with the specific HB-
EGF blocker CRM197 and measured its effect on doxorubicin-induced cell death. 
Remarkably, CRM197 treatment strongly enhances the apoptotic response to doxorubicin 3. Results    54 
 
when compared to doxorubicin alone, while CRM197 had only a minor effect on cell 
survival. Thus, these results point to a physiological significance of p38-dependent EGFR 
activation as a pathway employed by tumour cells to evade apoptosis upon chemotherapy-
induced cellular stress. 
 
 
 
Figure 28 Blockade of HB-EGF function enhances cell-death in response to doxorubicin. Cells were treated 
for 72 h with 10 µM doxorubicin and 10 µg/mL Crm197 every 24 h as indicated. After collection of cells in 
assay buffer, nuclei were stained with PI and analyzed by flow cytometric analysis. Quantification of four 
independent experiments (mean ± SD). *P < 0.001 for control versus doxorubicin. **P < 0.004 for doxorubicin 
versus doxorubicin + CRM197. 
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3.3.  Met Receptor transactivation by GPCRs and EGFR is mediated by ROS 
3.3.1. Analysis of cell surface protein phosphorylation in response to GPCR 
stimulation in pancreatic carcinoma cells 
In order to address the question whether other RTKs become activated and therefore tyrosine 
phosphorylated in response to GPCR agonist treatment, we stimulated DAN-G pancreatic 
carcinoma cells with LPA or Thrombin for 3 min. To selectively extract cell surface proteins, 
lectin chromatography was applied to the cell lysates using lentilsepharose and subsequently 
the fraction of glycosylated proteins that bind to lentilsepharose was analyzed for 
phosphotyrosine content.  
 
 
Figure 29 Lentilsepharose extraction of DAN-G pancreatic carcinoma cells. DAN-G pancreatic carcinoma 
cells were serum-starved for 24 hrs, preincubated with BB94 (10 µM) and stimulated with LPA (10 µM) or 
Thrombin (2U/mL) for 3 min. Cell lysates were extracted for glycosylated cell surface proteins using 
lentilsepharose. Extracts were applied to a 7.5-12% gradient SDS-PAGE, transferred to nitrocellulose and 
immunoblot analysis against phosphotyrosine was performed. 
 
As shown in Figure 29 both LPA and Thrombin induce phosphorylation of a 140 kDa protein 
band independent of metalloprotease function, as revealed by preincubation with BB94. This 
tyrosine phosphorylated protein is distinct of the EGFR, which migrates at 170 kDa.  3. Results    56 
 
3.3.2. GPCR-  and  EGFR  Stimulation induce Met receptor tyrosine 
phosphorylation 
The result of the experiment shown in Figure 29 revealed a yet unidentified protein which 
becomes tyrosine phosphorylated in response to GPCR agonist treatment. Since this protein 
was glycosylated it was likely to be a transmembrane protein. Moreover, the tyrosine 
phosphorylation of this molecule suggested a RTK as the protein of interest. Indeed 
immunoblot experiments identified this protein as the Met receptor and in consequence as a 
new RTK that becomes transactivated in response to GPCR stimulation (Figure 30).  
We used immunoblot analysis to assess the phosphorylation state of the Met receptor in 
response to treatment with different GPCR agonists. As shown in Figure 30, Met receptor 
tyrosine phosphorylation is rapidly induced in response to different GPCR ligands in the 
pancreatic carcinoma cell line DAN-G and the hepatocellular carcinoma cell lines HepG2 and 
HuH7 (Figure 30).  
 
 
Figure 30 GPCR agonists and EGF induce Met receptor transactivation. Cells were serum-starved for 24 
hrs, treated with lysophosphatidic acid (LPA, 10 µM), Bradykinin (BK, 2 µM), Thrombin (Thr, 2U/mL), 
Carbachol (Car, 10 µM) or EGF (4 ng/mL) as indicated for 3 min. Following immunoprecipitation (IP) of cell 
extracts with anti-Met antibody proteins were immunoblotted (IB) with anti-phosphotyrosine antibody and re-
probed with anti-Met antibody. The upper band of higher molecular weight shown in the DAN-G Met receptor 
reblot represents the precursor form of the Met receptor, consisting of both the α- and β-chain. The lower 
migrating band represents the processed mature β-chain.  
 
Time course experiments revealed that this activation occurs readily after 3 minutes and 
declines after 7 to 15 minutes (Figure 31), demonstrating a rapid and transient transactivation 
of the Met receptor. Interestingly, not only GPCR ligands but also EGF induced stimulation 3. Results    57 
 
of the Met receptor (Figure 30). In both cases Met receptor tyrosine phosphorylation induced 
by its transactivation resembles stimulation by 4 ng/mL exogenous HGF (Figure 32). 
 
 
Figure 31 Time course of GPCR- and EGF-induced Met receptor transactivation. Cells were stimulated 
with LPA (10 µM) for the indicated time periods. Cell lysates were treated as described under Figure 30. 
 
3.3.3. GPCR-induced Met Transactivation occurs independent of EGFR kinase 
activity 
EGFR signal transactivation is the so far best characterized GPCR-RTK cross-talk 
mechanism. As EGFR-Met association and phosphorylation of Met by the EGFR's kinase 
activity have been proposed in previous reports (Jo et al., 2000; Pai et al., 2003), we wanted to 
investigate whether GPCR-Met transactivation occurs via this previously suggested 
mechanism. This putative signalling pathway renders the Met receptor as a direct signaling 
partner of the EGFR.  
To address this question we used the EGFR kinase specific inhibitor AG1478 to block EGFR-
dependent phosphorylation events. As demonstrated in Figure 32, blockade of the EGFR 
kinase activity did not interfere with GPCR-induced Met phosphorylation, demonstrating that 
the EGFR kinase is dispensable for Met transactivation in response to treatment with GPCR 
agonists. In contrast, GPCR-induced EGFR signal transactivation is blocked by AG1478 
treatment, as transactivation of the EGFR depends on its kinase activity (Daub et al., 1996; 
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Figure 32 GPCR-induced Met transactivation is independent of EGFR kinase activity. DAN-G (A) and 
HepG2 (B) cells were pre-treated with AG1478 (250 nM) or an equal volume of empty vehicle (DMSO) for 20 
min and subsequently stimulated with LPA (10 µM), Thr (2U/mL), EGF (4 ng/mL) or HGF (4 ng/mL) as 
positive control for 3 min. Following immunoprecipitation of cell extracts with anti-Met antibody proteins were 
immunoblotted with anti-phosphotyrosine antibody and reprobed with anti-Met antibody. EGFR phosphorylation 
content was analyzed by immunoprecipitation of cell extracts with anti-EGFR antibody and immunoblotting 
with anti-phosphotyrosine. The same filters were reprobed with anti-EGFR antibody. 
 
As anticipated, Met transactivation by EGF was abrogated by preincubation with AG1478 
(Figure 32 A/B, lower panel), as the EGFR kinase is crucial to transmit the EGF-stimulated 
signal, regardless of direct association or an indirect communication with the Met receptor. 
But since no co-precipitation between the EGFR and Met receptor or vice versa could be 
detected, neither in unstimulated nor in stimulated cells, these observations suggest a 
mechanism distinct of RTK association between the EGFR and the Met receptor for Met 
transactivation. 
3.3.4. LPA-induced Met transactivation is independent of Src, PKC, PI3K and 
MEK1/2 activity 
To further investigate the mechanism leading to Met receptor transactivation we used 
different inhibitors against cellular signalling molecules that have earlier been revealed as 
GPCR effector molecules and which have been implicated in GPCR-RTK cross-talk (Wetzker 
and Bohmer, 2003). Figure 33 shows that preincubation of DAN-G cells with inhibitors 
against Src (PP1), PKC (GF109203X), PI3K (LY204002) or MEK1/2 had no effect on Met 
receptor transactivation, suggesting that these signalling proteins are not involved as upstream 
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Figure 33 Inhibition of Src, PKC, PI3K and MEK1/2 has no effect on Met receptor transactivation. DAN-
G pancreatic carcinoma cells were serum-starved for 24 hrs, preincubated with PP1 (10 µM, 30 min), 
GY109203X (10 µM, 30 min), LY294002 (10 µM, 30 min) or PD98059 (25 µM, 60 min) and stimulated with 
LPA (10 µM) for 3 min. Met receptor was immunoprecipitated and analyzed for phosphotyrosine content. The 
same filter was stripped and reprobed for Met receptor content. 
 
3.3.5.  Met receptor transactivation is independent of serine proteases 
The ligand for the Met RTK HGF is secreted from its producing cell and has to be activated 
by serine proteases to become active. Although HGF is not a transmembrane protein, this 
proteolytic activation step could potentially resemble the metalloprotease-dependent shedding 
event involved in EGFR signal transactivation. To test this hypothesis we used different 
serine protease inhibitors to interfere with the putatively GPCR-induced proteolytic activation 
step of HGF. The serine protease inhibitor aprotinin has earlier been used to block activation 
of HGF (Li et al., 1998). As shown in Figure 34, preincubation of DAN-G cells with aprotinin 
had no effect on Met receptor transactivation by LPA. Interestingly, BB94 exerted also no 
effect on Met receptor tyrosine phosphorylation. Since aprotinin does not inhibit all serine 
proteases, we used the stronger serine protease inhibitor Pefabloc to further substantiate this 
result. In agreement with the result obtained in Figure 34, Figure 35 shows that inhibition of 
serine protease-dependent shedding events has no effect on Met receptor transactivation. 
Higher concentrations of 4 mM Pefabloc reduced the overall level of Met receptor, both the 
precursor and the mature β-chain form (Figure 35). 
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Figure 34 Inhibition of serine proteases by aprotinin has no effect on Met receptor transactivation. DAN-G 
cells were preincubated with 100 µg/mL aprotinin (Aprot.) for 60 min, AG1478 (250 nM, 20 min) or BB94 (10 
µM, 20 min), subsequently stimulated with LPA (10 µM) or EGF (2 ng/mL) for 3 min and Met receptor 
phosphorylation was assessed as in Figure 33. 
 
 
Figure 35 Met receptor transactivation is not affected by inhibition of serine proteases with Pefabloc . 
Serum-starved DAN-G cells were pre-incubated with the indicated concentrations of Pefabloc for 60 min and 
stimulated with LPA (10 µM) or Thr (2 U/mL) for 3 min. Met receptor phosphorylation was assessed as 
described in Figure 33. 
 
3.3.6.  GPCR- and EGF-stimulated ROS production in carcinoma cell lines 
Inactivation of tyrosine phosphatases by growth factor-induced production of ROS has been 
frequently implicated in the activation of RTKs (Bae et al., 1997; Finkel, 2003; Rhee et al., 
2000; Sundaresan et al., 1995; Ushio-Fukai et al., 2001). Since the rapid and transient 
activation mechanism revealed by time course experiments (Figure 31) is in good agreement 
with a rapid and transient production of ROS, we asked whether Met receptor transactivation 
is mediated through a growth factor-stimulated increase in the level of reactive oxygen 
intermediates. Thus we used the fluorescence dye dichlorofluorescein diactate (DCF-DA) to 
detect ROS production. DCF-DA is a membrane-permeable non-fluorescent compound, 
which is deesterified inside the cell. Subsequent oxidation of dichlorofluorescein generates 
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subsequent stimulation with EGF or the GPCR-ligands LPA and Thrombin clearly 
demonstrated an increase of reactive oxygen species within the cell (Figure 36).  
 
Figure 36 GPCR agonists and EGF increase ROS production in DAN-G and HepG2 cells. (A/B) Cells were 
seeded into 6-well dishes, grown for 48 hrs and incubated with 2’,7’-dichlorofluorescein diacetate (DCF-DA, 20 
µM) for 30 min. After stimulation with LPA (10 µM), Thr (2 U/mL), EGF (4 ng/mL) or hydrogen peroxide 
(H2O2, 500 µM) as a positive control for 15 min cells were collected, resuspended in PBS supplemented with 
propidium iodide and immediately analyzed by flow cytometric analysis. 
 
To further substantiate the role of ROS in the Met receptor transactivation mechanism we 
preincubated the cells with the reducing agent epigallocatechin gallate (EGCG).  As 
demonstrated in Figure 37, EGCG treatment of DAN-G cells interfered with EGF- and 3. Results    62 
 
GPCR-induced Met receptor tyrosine phosphorylation, underlining the involvement of ROS 
in this signaling pathway. On the other hand, EGCG preincubation leaves EGFR signal 
transactivation unaffected (Figure 37). Taken together, these results demonstrate the critical 
role of ROS production in the Met receptor transactivation mechanism.  
 
 
Figure 37 EGCG abolishes Met receptor transactivation. Cells were preincubated with epigallocatechin 
gallate (EGCG, 40 µM) for 60 min. Following stimulation as described under Figure 32 Met or EGFR 
respectively were immunoprecipitated and analyzed for phosphotyrosine content. The same filters were stripped 
and reprobed for Met and EGFR respectively. 
 
3.3.7.  Met receptor transactivation involves NADPH oxidase activity 
Recent investigations implicated membrane-bound NADPH oxidases in the growth factor 
stimulated production of ROS (reviewed in (Finkel, 2000; Finkel, 2003; Rhee et al., 2000)). 
To investigate whether Nox enzymes are involved in Met receptor transactivation, we used 
the Nox inhibitor diphenyleneiodonium chloride (DPI) to interfere with Nox-dependent ROS 
production and analyzed Met receptor tyrosine phosphorylation by immunoblot analysis. As 
shown in Figure 38, blockade of Nox function interfered with both GPCR- and EGF-induced 
Met phosphorylation in HepG2 and DAN-G cells, suggesting the involvement of Nox in Met 
receptor transactivation. EGFR signal transactivation was not affected by DPI treatment 
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Figure 38 ROS production depends on NADPH-oxidase activity. (A/B) Following preincubation with 
diphenyleneiodonium chloride (DPI, 10 µM) for 30 min, cells were stimulated as indicated and Met (upper 
panel) or EGFR (lower panel) were analyzed for phosphotyrosine content by immunoblot analysis.  
 
Investigations on regulatory mechanisms of Nox activity implicated the small GTPase Rac as 
one of the cytosolic components of the Nox enzyme complex (Sundaresan et al., 1996). 
Moreover, Rac has been shown as a downstream signalling target of both GPCRs and RTKs 
(LIT). Therefore we used the ToxinB, which blocks GTPases of the Rac, Rho and Cdc42 
family, to interfere with Rac function (Schiavo and van der Goot, 2001). Indeed, 
preincubation with ToxinB abrogated both GPCR- and EGF-induced Met transactivation 
(Figure 39), while EGFR signal transactivation was not influenced (Figure 39). These data 
support the mechanistic concept that Nox enzymes are involved in the cross-talk mechanism 
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Figure 39 ToxinB treatment blocks Met receptor transactivation. Cells were pretreated with ToxinB (2 
ng/mL) for 2 hrs, stimulated as indicated and analyzed as described under Figure 38. 
 
3.3.8.  Met receptor transactivation is independent of NO-synthase activity 
Besides reactive oxygen species also reactive nitrogen species (RNS) have gained increasing 
attention as signalling intermediates (Schindler and Bogdan, 2001). To test whether the 
production of RNS plays a role in Met receptor transactivation, we used the specific NO-
synthase inhibitor N
G-Monomethyl-L-arginine monoactate (L-NMMA) to interfere with RNS 
production. As shown in Figure 40 inhibition of DAN-G cells with L-NMMA did neither 
effect GPCR-induced nor EGF-stimulated Met receptor transactivation, nor was HGF 
stimulation used as a positive control affected. 
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Figure 40 Met receptor transactivation is independent of NO-synthase activity. DAN-G cells were serum-
starved and treated with L-NMMA (100 µM, 30 min). Following stimulation with LPA (10 µM), Thr (2 U/mL), 
EGF (4 ng/mL) or HGF (4 ng/mL), Met receptor and EGFR were immunoprecipitated from split cell lysates and 
immunoblot analysis for phosphotyrosine content was performed. The same blots were stripped and probed for 
Met or EGFR protein, respectively. 
 
3.3.9. Met transactivation induces dissociation of the ß-Catenin-Met receptor 
complex in HuH7 and DAN-G cells 
ß-catenin has been shown to be constitutively associated with the Met receptor in hepatoma 
and hepatocellular carcinoma cells (Herynk et al., 2003; Hiscox and Jiang, 1999a). 
Immunoprecipitation of Met in the hepatocellular carcinoma cell line HuH7 co-precipitated ß-
catenin (Figure 41), which is constitutively associated and tyrosine phosphorylated in HuH7 
cells (Figure 41, upper panel). Stimulation of Met transactivation by both GPCR ligands and 
EGF induced the dissociation of this ß-catenin-Met receptor complex (Figure 41). 
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Figure 41 Met transactivation induces dissociation of the Met-ß-catenin complex. HuH7 cells were serum-
starved for 24 hrs and stimulated as indicated. Following immunoprecipitation of the Met receptor filters were 
probed for phosphotyrosine content or ß-catenin. 
 
To analyze the translocation of ß-catenin in response to Met receptor transactivation we used 
the differential detergent fractionation technique to prepare cytoplasmic-, membrane- and 
nuclei-enriched fractions. Figure 42 demonstrates that stimulation of HuH7 and DAN-G cells 
with LPA, Thrombin, EGF or HGF induced translocation of ß-catenin from the membrane to 
the cytoplasmic fraction and an increase of ß-catenin in the nuclei-enriched fraction. 
 
 
Figure 42 Met transactivation induces nuclear translocation of ß-catenin. DAN-G or HuH7 cells were 
stimulated as depicted and subsequently cytoplasmic-, membrane- and nucleic-enriched fractions were isolated 
by differential detergent fractionation (DDF) as described under materials and methods. Equal amounts of total 
lysates were analyzed for ß-catenin content by immunoblot analysis. 
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4. Discussion 
Deregulated RTK signalling has been frequently linked to the development and progression of 
pathophysiological disorders such as cancer (Blume-Jensen and Hunter, 2001; Zwick et al., 
2001). Besides the EGFR and its relative HER2 which have been early on recognized as 
signalling proteins with a high oncogenic signalling potential, RTKs of other families have 
been implicated in the pathogenesis of cancer, such as c-Met or the platelet-derived growth 
factor receptor (PDGFR). In addition to RTKs the autocrine production of GPCR agonists has 
been frequently associated with different types of human cancer (Marinissen and Gutkind, 
2001; Moody et al., 2003). With respect to the pathophysiological significance of cell surface 
receptor signalling this study investigates the role of RTK activation mechanism in response 
to heterogeneous stimuli including GPCR agonists and cellular stress stimuli in human 
tumour cell lines. 
4.1.  Metalloprotease-mediated EGFR signal transactivation in NSCLC and 
pancreatic carcinoma cell lines 
Previous publications implicated the EGFR in the molecular pathology of both NSCLC and 
pancreatic carcinoma (Bardeesy and DePinho, 2002; Sridhar et al., 2003). Moreover GPCR 
agonist signalling loops have been demonstrated in both types of cancer (Moody, 1996; 
Moody et al., 2003; Siegfried et al., 1999).  
The data presented in this study provide evidence for the functional relevance of GPCR 
stimulation and EGFR downstream signalling pathways employing metalloprotease-
dependent EGFR signal transactivation. Stimulation with GPCR ligands induces the rapid 
tyrosine phosphorylation of the EGFR in both tumour types (Figure 6 and Figure 7), 
depending on the cellular system and the stimulus investigated. The NSCLC cell lines A549 
and Calu-6 reveal only a weak GPCR-induced stimulation of  EGFR phosphorylation which 
can be attributed to an increased basal receptor tyrosine phosphorylation. In both carcinoma 
cell lines the small G protein Ras is constitutively activated due to mutation (Heasley et al., 
1997; Rajesh et al., 1999) which has been linked to autocrine signalling loops involving the 
EGFR and its ligands leading to high basal tyrosine phosphorylation (Watanabe et al., 1996; 
Zushi et al., 1997).   
Preincubation with the metalloprotease inhibitor batimastat abrogated GPCR-induced EGFR 
phosphorylation demonstrating the involvement of a metalloprotease activity. On the other 
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function in BxPc-3 cells (Figure 6), suggesting a ligand-independent pathway in parallel to 
the ligand-dependent EGFR signal transactivation in this cell line.  
Besides the EGFR itself, GPCR agonist treatment induces EGFR characteristic downstream 
signalling cascades. Metalloprotease-dependent phosphorylation of the adaptor protein Shc 
occurs in response to GPCR stimulation ( 
Figure 8), which is linked to stimulation of the MAPKs Erk1/2 (Figure 9/Figure 10). The role 
of the EGFR as a transducer of GPCR stimulation to the MAPKs Erk1/2 has been 
demonstrated in a variety of other cell systems, including Rat-1 (Daub et al., 1996), Cos-7 
(Daub et al., 1997; Prenzel et al., 1999), PC-12 (Kim et al., 2000), HEK-293 cells (Della 
Rocca et al., 1999) and head and neck squamous cell carcinoma (Gschwind et al., 2002). 
Interestingly, in the NSCLC cell line NCI-H292, LPA induces an increase in DNA synthesis 
which depends on both EGFR kinase and metalloprotease function, indicating that 
metalloprotease-dependent EGFR signal transactivation in response to LPA treatment is 
capable of inducing cell proliferation in this cell line (Figure 11). In contrast, neither A549 or 
Calu-6 cells nor the pancreatic carcinoma cell lines DAN-G or BxPc-3 revealed a GPCR-
stimulated increase in DNA synthesis (data not shown). All of these cell lines harbour 
activating mutations of the Ras protein which accounts in particular for 90% of all pancreatic 
carcinoma (Bardeesy and DePinho, 2002; Watanabe et al., 1996; Zushi et al., 1997). In 
consequence the GPCR-induced EGFR and subsequent Ras activation might only provide 
weak enhancement compared to the constitutive activity. LPA- and other GPCR agonist-
stimulated DNA synthesis has also been observed in Rat-1, Swiss 3T3 and HNSCC cells 
(Daub et al., 1996; Gschwind et al., 2002; Santiskulvong et al., 2001). Together with these 
results the data presented in this study corroborate the instrumental role of the EGFR in 
linking GPCRs to mitogenic signals.   
4.2.  EGFR activation in response to cellular stress 
How mammalian cells respond to physical stress has been intensely studied, but, despite these 
extensive research efforts, various mechanistic aspects of stress-induced signalling have 
remained elusive (Benhar et al., 2002b; Finkel and Holbrook, 2000; Kamata and Hirata, 1999; 
Kyriakis and Avruch, 2001). The present study investigates growth factor-dependent 
mechanisms leading to EGFR and subsequent MAPK activation in response to osmotic and 
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4.2.1.  Osmotic and oxidative stress mediate metalloprotease- and HB-EGF 
dependent EGFR activation 
The data presented here demonstrate that EGFR phosphorylation induced by both osmotic and 
oxidative stress requires a metalloprotease activity triggering the release of mature HB-EGF 
in Cos-7 cells and human carcinoma cell lines (Figure 17). These findings significantly extent 
results from earlier reports, which indicated a role of mechanisms such as receptor 
aggregation, phosphatase inactivation or the stimulation of intracellular kinases in stress-
induced EGFR activation (Blanchetot et al., 2002; Knebel et al., 1996; Rosette and Karin, 
1996). These previously described mechanisms might contribute to the partially ligand-
independent EGFR phosphorylation in NCI-H292, whereas a ligand-dependent activation 
fully accounts for receptor phosphorylation by osmotic and oxidative stress in Cos-7 and 
TCC-Sup bladder carcinoma cells. Thus, the respective contribution of different routes 
leading to EGFR activation appears to depend on the cellular context. It is noteworthy that 
Chen et al. (Chen et al., 2001a) attributed the hydrogen peroxide-induced EGFR activation in 
Cos-7 cells to a ligand-independent mechanism involving c-Src. In contrast to these earlier 
observations, inhibition of EGFR activation by oxidative stress with the Src inhibitor PP2 in 
the same cell system could not be observed (Figure 13). Nishida et al. reported the activation 
of Gαi/o proteins by H2O2 due to oxidation of a cysteine residue which is characteristic for this 
Gα subfamily (Nishida et al., 2000; Nishida et al., 2002). Since these Gαi/o proteins are 
sensitive to pertussis toxin, a contribution of ROS-induced Gαi/o activation could be excluded 
by preincubation with the bacterial toxin (Figure 14). 
Stress-induced signalling might also trigger a positive feedback loop further enhancing 
ligand-dependent EGFR activation, since previous investigations revealed stress-induced 
expression of HB-EGF and amphiregulin (Miyazaki et al., 2001). Interestingly, Zenz et al. 
demonstrated a functional correlation between c-Jun, a downstream target of the JNK family, 
the EGFR and HB-EGF, as in c-Jun deficient keratinocytes both HB-EGF and EGFR 
expression was reduced (Zenz et al., 2003). 
4.2.2.  ADAM family proteases mediate stress-induced EGFR phosphorylation  
Although Frank et al. recently implicated HB-EGF in hydrogen peroxide-induced EGFR 
phosphorylation in vascular smooth muscle cells (Frank et al., 2003), the various components 
involved in this process have not been defined. This study provides experimental evidence 
that ADAM proteases are responsible for shedding of proHB-EGF upon cellular stress. 
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ADAM proteases (Gschwind et al., 2003; Yan et al., 2002), we found that two or more 
ADAM proteases become active upon cellular stress. ADAM17 appears to be generally 
involved in stress stimulated shedding events, while also ADAM9, ADAM10 and ADAM12 
can contribute depending on the cell system and type of stimulus. All of these enzymes have 
been previously implicated in EGF-like ligand shedding (Asakura et al., 2002; Izumi et al., 
1998; Lemjabbar and Basbaum, 2002; Yan et al., 2002). The identification of stress-induced 
ADAM family members distinct from those regulated through GPCRs is corroborated by 
previous reports demonstrating that ADAM9 cleaves proHB-EGF in response to TPA 
stimulation in VeroH cells (Izumi et al., 1998), while in the same cellular system proHB-EGF 
processing after LPA stimulation is independent of ADAM9 (Umata et al., 2001). Taken 
together, these data suggest that proHB-EGF sheddases are defined by both the cellular 
context and the stimulus. Moreover, ADAM9 knock-out mice lack an obvious phenotype and 
ADAM9 
-/- fibroblasts display no defects in proHB-EGF processing (Weskamp et al., 2002), 
which strongly argues for functional redundancy among proHB-EGF cleaving enzymes in 
vivo. 
4.2.3.  p38 controls EGFR activation upon cellular stress 
How are the metalloproteases of the ADAM family activated, finally leading to EGFR 
phosphorylation and downstream signalling responses? Previous reports demonstrated 
regulation of metalloprotease-mediated ectodomain cleavage of transmembrane proteins in 
response to growth factors and TPA by the MAPK ERK1/2, while the basal level of 
ectodomain shedding has been attributed to p38 activity (Fan and Derynck, 1999; Gechtman 
et al., 1999; Rizoli et al., 1999). Moreover, p38 has been implicated as an upstream mediator 
of the EGFR in the sorbitol-induced EGFR activation in human non-transformed 
keratinocytes (Cheng et al., 2002). In contrast to the results presented herein, the authors of 
this report excluded a ligand-dependent mechanism based on medium transfer experiments. 
As the released EGF-like ligand may be retained in the extracellular matrix through binding to 
heparan sulfate proteoglycans (Prenzel et al., 1999), an involvement of ligand-dependent 
EGFR activation cannot be ruled out by this type of experimental approach. These reports and 
the finding that p38 activity in our systems is independent of the EGFR phosphorylation state 
prompted us to ask whether stress-activated p38 is the upstream signalling element that 
controls ligand-dependent EGFR activation. Indeed, we found that preincubation with a 
specific p38 inhibitor abrogated stress-induced EGFR activation, while blocking ERK1/2 
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response to stress agents is independent of the EGFR as assessed by the EGFR selective 
inhibitor AG1478. Furthermore, time course experiments revealed that p38 activation 
precedes EGFR phosphorylation, which is a necessary prerequisite for p38 being located 
upstream of the EGFR, while ERK1/2 and JNK activation occurs even later. Together, these 
data suggest p38 as the upstream inducer of ligand-dependent EGFR activation and its 
subsequent downstream signalling. 
4.2.4. The role of HB-EGF function in doxorubicin-induced apoptosis of cancer 
cells 
Activation of ERK1/2 and JNK in response to oxidative and osmotic stress represents an 
important step in the cellular stress response (reviewed in (Kyriakis and Avruch, 2001)). 
Stress signalling via MAPKs is often increased in cancer cells, which frequently produce high 
levels of ROS per se (Burdon, 1995; Szatrowski and Nathan, 1991). Moreover, anticancer 
drugs or radiation therapy can further activate stress signalling cascades (Benhar et al., 
2002b), which has also been attributed to the production of ROS caused by these agents. 
Here, this study demonstrates that stress-induced ligand-dependent EGFR activation is a 
prerequisite for subsequent ERK1/2 and, to a lesser extent, also JNK MAPK activation 
(Figure 24/Figure 25). As ligand-dependent, EGFR-mediated MAPK signalling can control 
cell survival through induction of apoptosis regulators such as the Bcl-2 family (Jost et al., 
2001), it might also play a role in the protection of bladder carcinoma cells from doxorubicin-
induced apoptosis observed in our experiments. Consistent with this hypothesis, blockade of 
HB-EGF function strongly enhanced doxorubicin-induced cell death (Figure 28). As 
chemotherapeutic agents have been previously shown to activate stress signalling cascades 
(Benhar et al., 2002b; Losa et al., 2003; Sanchez-Prieto et al., 2000), this signalling 
mechanism provides a molecular explanation for the ability of tumour cells to evade drug-
induced cell death. Figure 43 schematically summarizes the results presented in this study as a 
model of metalloprotease- and HB-EGF-dependent EGFR activation upon cellular stress.  
Increasing evidence implicates particularly ROS-induced oxidative stress in a variety of 
human disorders as diverse as cardiovascular, neurodegenerative or hyperproliferative 
diseases and cancer. Therefore, these results are of special significance for the understanding 
of pathophysiological disorders and the development of respective therapeutic approaches.  
The findings presented herein emphasize the importance of ADAM family proteases and HB-
EGF as critical mediators of the stress response in human cancer cells and suggest that cross-4. Discussion    72 
 
communication between different groups of MAPK employs ADAM proteases and the EGFR 
as signalling intermediates.   
 
 
Figure 43 Model of the cellular stress response mediated by metalloprotease-dependent release of HB-
EGF. Stress stimuli such as oxidative or osmotic stress, but also chemotherapeutics activate p38. p38 is able to 
induce the activity of ADAM family proteases leading to specific processing of proHB-EGF, release of the 
mature growth factor and subsequent EGFR stimulation. Dependent on this mechanistic concept EGFR 
characteristic downstream signalling cascades are induced comprising ERK1/2 and JNK activity, and cellular 
responses such as cell survival in response to stress are modulated. 
 
4.3.  Met receptor transactivation 
Cross-talk between cell surface receptors has been early recognized as a crucial signaling 
mechanism to expand the cellular communication network. Related RTKs such as members 
of the EGFR family are capable of forming heterodimers thereby affecting downstream 
signaling pathways (Yarden, 2001). A further layer of complexity was added by the discovery 
of the heterogeneous GPCR-RTK cross-talk mechanism with EGFR signal transactivation 
serving as the prototypic interreceptor signaling pathway (Daub et al., 1996; Prenzel et al., 
1999). In addition to above mentioned pathways integrins and cytokine receptors have also 
been reported to be involved in cross-communication (Moro et al., 1998; Trusolino et al., 4. Discussion    73 
 
2001) (Yamauchi et al., 1997). Therefore, increasing interest focuses on these heterogeneous 
interreceptor cross-communication networks. 
4.3.1. EGF-induced  Met  receptor phoshorylation 
This study provides experimental evidence that the EGFR transactivates the Met RTK in 
human pancreatic and hepatocellular carcinoma cells. Previous investigations demonstrated 
cross-talk between both receptors on the transcriptional level and Met ectodomain shedding in 
response to EGFR signal transactivation (Bergstrom et al., 2000; Nath et al., 2001). Direct 
association of Met with and phosphorylation by the EGFR has been suggested as the 
underlying mechanism of this cross-communication (Jo et al., 2000). EGF- or TGF-α-induced 
Met phosphorylation and Met-EGFR co-precipitation were restricted to A431 cells which 
overexpress EGFR due to gene amplification. However, in hepatocellular carcinoma cell lines 
that express moderate levels of both receptors, the authors could neither detect transactivation 
of Met nor coprecipitation of Met and EGFR (Jo et al., 2000). Since in this study neither 
association of Met and EGFR was found in hepatocellular and pancreatic carcinoma cells, it 
was investigated whether an alternative mechanism than heterodimerization might account for 
Met receptor transactivation. 
4.3.2.  The role of ROS production in EGF-stimulated Met receptor 
transactivation  
Using a flow cytometric analysis of cells stained with the redox-sensitive fluorescent dye 
DCF-DA it could be shown that reactive oxygen species are generated in response to EGF 
treatment (Figure 36). The critical role of ROS in this cross-talk mechanism was further 
corroborated by the finding that preincubation with the reducing agent EGCG interferes with 
Met receptor transactivation (Figure 37). While different cellular sources for ROS have been 
reported (Thannickal and Fanburg, 2000), the data of this study provide evidence for the 
involvement of plasma membrane bound NADPH oxidases (Figure 37/Figure 38/Figure 39). 
These enzymes have previously been implicated in the acute and rapid production of ROS in 
response to growth factor treatment (Finkel, 2000; Finkel, 2003; Rhee et al., 2000; Thannickal 
and Fanburg, 2000). Moreover, the finding that inhibition of the small GTPases Rac, Rho and 
Cdc42 by ToxinB interfered with Met transactivation does also point towards an involvement 
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4.3.3. GPCR  agonist-induced  Met receptor transactivation 
In addition to EGF, also stimulation of cells with GPCR ligands such as LPA, Bradykinin, 
Thrombin or Carbachol induced the rapid and transient phosphorylation of the Met receptor 
(Figure 30). Analogous to EGF-induced Met transactivation it could be demonstrated that 
GPCR-induced Met phosphorylation critically depends on the production of ROS by NADPH 
oxidases (Figure 36/ Figure 37/ Figure 38/Figure 39). Flow cytometric analysis showed that 
stimulation with either LPA, Thrombin or EGF induced a moderate shift towards higher 
fluorescence compared to stimulation with the positive control H2O2. This observation can be 
anticipated as the ROS production induced by physiologic stimuli in epithelial cells should be 
strictly limited in its duration and localization, which are in this case distinct microdomains at 
the plasma membrane. In consequence, only a fraction of the fluorescent dye distributed 
throughout the cell can be oxidized in response to growth factor treatment. The increase in 
ROS production corresponds to a moderate increase of Met receptor tyrosine phosphorylation, 
which is equivalent to stimulation with 4 ng/mL HGF (Figure 32). Interestingly, this level of 
receptor tyrosine phosphorylation is comparable to the level of EGFR transactivation reached 
by GPCR ligands. 
Very recently, Pai and colleagues reported that prostaglandine E2 is capable to induce Met 
receptor tyrosine phosphorylation in colorectal carcinoma cells (Pai et al., 2002). They 
suggested an indirect mechanism involving the EGFR, since preincubation with the EGFR 
kinase specific inhibitor AG1478 abolished Met activation (Pai et al., 2002). Interestingly, 
EGF treatment did not significantly enhance Met phosphorylation. However, treatment of 
hepatocellular and pancreatic carcinoma cells with AG1478 did not affect Met 
phosphorylation in response to GPCR agonists, suggesting that GPCR-induced Met 
phosphorylation does not dependent on EGFR kinase activity in these cellular systems. Since 
the EGFR itself is able to induce ROS production (Bae et al., 1997), in some cellular systems 
EGFR signal transactivation might be used by GPCRs that are unable to directly stimulate the 
production of reactive oxygen intermediates to induce ROS-dependent Met transactivation.  
The involvement of ROS in Met transactivation is corroborated by the previous findings that 
PDGF induces ROS production in HepG2 cells (Bae et al., 2000). The same result has been 
obtained in A431 cells in response to EGF treatment (Bae et al., 1997). Since in colorectal 
carcinoma cells that have been used in the study by Pai and colleagues (Pai et al., 2002) 
functional components of Nox enzymes have been found (Kikuchi et al., 2000; Perner et al., 
2003), the results presented herein can provide a molecular explanation for activation of Met 
in response to heterogeneous stimuli in the cellular systems reported by Stolz et al. and Pai et 4. Discussion    75 
 
al. (Jo et al., 2000; Pai et al., 2002). ROS have been previously implicated in receptor cross-
talk mechanisms in particular in endothelial or vascular smooth muscle cells, such as 
Angiotensin II-induced EGFR transactivation (Ushio-Fukai et al., 2001). The results of this 
study extend this finding and demonstrate this functional correlation of GPCR and Met cross-
talk in transformed epithelial cells of hepatocellular and pancreatic carcinoma. 
4.3.4. Met receptor transactivation induces dissociation of the β-catenin-Met 
complex 
Previous reports demonstrated the association between the Met receptor and ß-catenin   
(Hiscox and Jiang, 1999a; Monga et al., 2002; Muller et al., 2002). Interestingly, it could be 
shown that in the hepatocellular carcinoma cell line HuH7 and in the pancreatic carcinoma 
cell line DAN-G not only direct Met activation by HGF but also Met transactivation by 
GPCR agonists and EGF stimulates the nuclear translocation of ß-catenin. Nuclear ß-catenin 
has been associated with enhanced transcription of TCF target genes that are involved in 
epithelial-to-mesenchymal-transition and the development of an invasive phenotype (Behrens, 
2000; Conacci-Sorrell et al., 2002; Mareel and Leroy, 2003). The Met receptor has been 
shown to be instrumental to invasive growth in both physiological  and pathophysiological 
signaling context (Trusolino and Comoglio, 2002). Interestingly, previous reports implicated 
co-expression of Met and EGFR in tumor progression and development in gastrinoma and 
hepatocellular carcinoma. In the latter, overexpression of both Met and the EGFR is 
associated with increased tumor size, tumor stage, lymph node metastasis and poor prognosis 
and reduced survival (Peghini et al., 2002). Daveau et al. reported the presence of enhanced 
levels of mRNA for both receptors in particular in poorly differentiated tumors and in patients 
with early tumor recurrence (Daveau et al., 2003). Noteworthy, Miura and colleagues 
demonstrated that ROS potentiated the invasive activity of hepatoma cells by 
autocrine/paracrine loop of HGF (Miura et al., 2003). 
The results of this study provide a molecular mechanism for EGFR-dependent transactivation 
of the Met receptor and extend this concept to cross-talk involving GPCRs and Met. With 
respect to the outstanding role of the Met receptor in tumor invasion, these findings are of 
special significance for the understanding of cancer progression and metastasis in response to 
heterogeneous growth factor stimulation involving the Met receptor. Figure 44 shows a model 
of GPCR-induced Met receptor transactivation in hepatocellular and pancreatic carcinoma 
cells based on the results presented in this study. In this model, GPCR stimulation induces in 
a Rac-dependent manner a NADPH oxidase activity resulting in an increased ROS 4. Discussion    76 
 
production. The rise in ROS levels inactivates a yet unidentified phosphatase, thereby 
increasing the basal phosphorylation of the Met receptor giving rise to a phosphorylation 
signal. 
 
 
Figure 44 Model of GPCR- and EGFR-induced Met receptor transactivation. Stimulation of both GPCRs 
and EGFR induce in a Rac-dependent fashion the production of ROS by NADPH-oxidase enzyme complexes. 
Following inactivation of one or more Met specific phosphatase the equilibrium of phosphorylated and 
dephosphorylated receptor becomes shifted towards the phosphorylated state. 
4.4. Perspectives 
An increasing number of reports underlines the role of ligand-dependent EGFR signal 
transactivation in diverse human disorders, including cancer, cardiac and gastrointestinal 
hypertrophy, helicobacter pylori-induced pathophysiological processes or cystic fibrosis 
(reviewed in (Fischer et al., 2003)). In particular the role of ADAM family metalloproteases 
in EGFR activation has gained increasing interest and consequently different members of this 
family could be identified as critical mediators of EGFR signal transactivation. Since this 
mechanism provides a link to couple autocrine GPCR signalling loops to the EGFR, future 
work has to focus on the relation of deregulated GPCR signalling and the TMPS pathway. Of 
special significance are elements that link GPCRs to the respective metalloprotease-ligand 
pair since they might provide targets for specific therapeutical intervention. The 
developmental role of proteins which participate in the transactivation pathway such as 
ADAM17 and HB-EGF has been addressed by studies using knock-out mice (Jackson et al., 
2003; Peschon et al., 1998). However, both the physiological and pathophysiological role of 
these molecules within the EGFR signal transactivation in vivo awaits further elucidation.  4. Discussion    77 
 
An additional layer of complexity was added by the finding that different metalloprotease-
ligand combinations can exist, depending on the cellular context and stimulus (Fischer et al., 
2003). In addition, the present study demonstrates within the context of cellular stress 
signalling situations that different ADAM proteases are able to induce cleavage of a single 
distinct EGF-like ligand, while other EGF-related growth factors are present. Future studies 
will be necessary to identify the regulatory mechanisms that determine the substrate 
specificity of these metalloproteases. The results presented in this study indicate a role for the 
MAPK p38 in the ligand-dependent EGFR activation upon cellular stress, while the 
mechanistic details linking p38 to activation of ADAM proteases still have to be elucidated. 
The data presented here point out the role of EGF-like ligand processing as a mechanistic 
concept for tumour cells to evade chemotherapy. However, the broad significance of the 
mechanisms elucidated in this study and the potential relevance towards the development of 
targeted cancer therapies will need to be addressed in future studies on the basis of both cell 
culture models and primary tumours. Of special interest is the expression analysis of tumours 
based on the characterization of the signalling pathways relevant to resistance to 
chemotherapy. While antibodies directed against the EGFR itself or its relative HER2 are 
readily used in combination with chemotherapy (Zwick et al., 2001), targeting a distinct 
growth factor is likely to provide an enhanced selectivity. 
This work provides evidence for the GPCR- and EGFR-induced transactivation of the Met 
receptor tyrosine kinase. The mechanistic concept involving the NADPH oxidase-dependent 
acute production of ROS emphasizes the role of reactive oxygen intermediates as signal 
transducers and supports the concept for a role of deregulated radical signalling in 
pathophysiological disorders. Increased ROS levels have been early linked to tumour cells 
(Szatrowski and Nathan, 1991). While this increased production has been associated with an 
high metabolic rate in these cells, recent reports suggest a role of hydrogen-peroxide 
producing enzymes in tumour development and progression (Arbiser et al., 2002; Arnold et 
al., 2001; Suh et al., 1999). The results of this study reveal the Met receptor as a target of 
enhanced ROS levels. However, future studies have to identify further components of this 
signalling mechanism, such as the phosphatase which becomes inactivated in response to 
ROS production. 
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5. Summary 
The classical view of RTK activation comprises direct stimulation of  the receptor by its 
ligand. The finding that heterogeneous stimuli distinct of the cognate ligand induce 
phosphorylation of RTKs such as the EGFR was attributed to intracellular signal transduction 
pathways such as the inactivation of phosphatases or the action of cellular tyrosine kinases. 
However, recent investigations demonstrated that EGFR signal transactivation in response to 
GPCR stimulation relies on a ligand-dependent mechanism, combining the wide diversity of 
GPCRs with the oncogenic EGFR signalling potential. This study investigated whether this 
signalling pathway occurs in pancreatic and non-small cell lung carcinoma. In both tumour 
types metalloprotease-dependent transactivation of the EGFR was observed and linked to 
activation of the mitogen-activated protein kinases ERK1/2. Interestingly, LPA treatment 
enhanced DNA synthesis in a NSCLC cell line, indicating a potential role for EGFR signal 
transactivation in tumour cell proliferation.  
Cellular stress stimuli induce signalling cascades such as the EGFR and MAPKs in 
mammalian cells. Similar to EGFR signal transactivation receptor stimulation was thought to 
rely on ligand-independent mechanisms. In contrast, this study provides evidence for the 
involvement of an EGF-like ligand in stress-induced EGFR phosphorylation. The mechanism 
comprises p38-dependent activation of ADAM family proteases releasing HB-EGF and can 
be linked to ERK1/2 and JNK activation. Interestingly, cell death in response to doxorubicin 
treatment, which induces p38 activity, is strongly enhanced by blockade of HB-EGF, 
suggesting a role of this signalling pathway for tumour cells to evade drug-induced cell death. 
Since cross-communication between different classes of cell surface receptors gains 
increasing interest, this study addressed the question whether other RTKs than the EGFR can 
be transactivated in epithelial tumour cells. This work demonstrates GPCR- and EGFR-
induced Met receptor transactivation depending on the rapid and transient production of 
reactive oxygen species. This Met receptor transactivation induces dissociation of the Met-β-
catenin complex and subsequent nuclear translocation of β-catenin, providing a link between 
GPCR and EGFR signalling to the Met receptor and its potent invasive signalling capacities. 
Taken together, these data emphasize the significance of communication between hetero-
geneous receptor signalling pathways. While interreceptor cross-talk provides an mean of 
signal fine tuning, these data indicate a role of such signalling pathways for tumour cells to 
stimulate cellular proliferation, modulate their invasive behaviour or allow them to evade 
from drug-induced cell death. 6. References    79 
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7. Abbreviations 
A A          A m i n o   a c i d  
Ab         Antibody 
ADAM        A  disintegrin  and  metalloprotease  domain 
Ampr          Ampicilline resistence 
APS         Ammoniumpersulfate 
AR         Amphiregulin 
ATP         Adenosintriphosphate 
bp         Base  pairs 
BSA         Bovine  serum  albumin 
° C          D e g r e e   c e l s i u s  
cAMP         Cyclic  adenosinmonophosphate 
Ca2 +          Calcium Ions 
C a M          K i n a s e   C a 2+-calmodulin-dependent kinase 
cDNA         Complementary  DNA 
c-fos         Cellular  homologue  to  v-fos  (FBJ  murine 
osteosarcoma viral oncogene) 
c-jun         Cellular  homologue  to  v-jun  (avian  sarcoma  virus 
17 oncogene) 
DAG         Diacylglycerol 
DMEM        Dulbecco's  modified  eagle  medium 
DN         Dominant  negative 
DMSO       Dimethylsulfoxide 
DNA         Desoxyribonukleic  acid 
dsDNA        Dooble-stranded  DNA 
DTT         Dithiothreitol 
ECL         Enhanced  chemiluminescence 
ECM       Extracellular  matrix 
EDTA         Ethlendiamintetraacetate 
EGF         Epidermal  growth  factor 
EGFR         Epidermal  growth  factor  receptor 
EGTA         Ethylene  glycol-bis(2-aminoethyl)- 
N,N,N',N'-tetraacetic acid 
ERK         Extracellular  signal-regulated  kinase 
FAK         Focal  adhesion  kinase 
FCS         Fetal  calf  serum 
FGF         Fibroblast  growth  factor 
FGFR         Fibroblast  growth  factor  receptor 
g          G r a m m  
Gab1         Grb2-associated  binder-1 
Gab2         Grb2-associated  binder-2 
GDP         Guanosindiphosphate 
GPCR         G  protein-coupled  receptor 
Grb2         Growth  factor receptor binding protein 2 
GST         Glutathion-S-transferase 
GTP         Guanosintriphosphate 
h         Hour 
HA         Hemagglutinin 
HB-EGF        Heparin-binding  EGF-like  growth  factor 7. Abbreviations    97 
 
H2Obidest        Twice-destilled, deionised Water 
HEPES        N-(2-Hydroxyethyl)-piperazin-N‘-2- 
Ethansulfonic acid 
H E R          H u m a n   E G F R - r e l a t e d  
HGF       Hepatocyte  Growth  Factor 
HNSCC        Head  and  neck squamous cell carcinoma 
Ig         Immunglobulin 
IP         Immunoprecipitation 
IP3          Inositol-1,4,5-trisphosphate 
IPTG         Isopropyl-ß-thiogalactopyranoside 
JNK         c-Jun  N-terminal  kinase 
kb         Kilobase 
kDa         Kilodalton 
l          L i t e r  
LPA         Lysophosphatydic  acid 
µ          M i c r o  
m          M i l l i  
M          M o l a r  
MAP         Mitogen-activated  protein 
MAPK       MAP  kinase 
MBP         Myelin  basic  protein 
MEK         MAPK/ERK  Kinase 
m i n          M i n u t e  
MMP         Matrix  metalloprotease 
n          N a n o  
N R G        N e u r e g u l i n  
Nox       NADPH  oxidase 
O D          O p t i c a l   d e n s i t y  
p.a.         Per  analysis 
PBS         Phosphate-buffered  saline 
PCR         Polymerase  chain  reaction 
PDGF         Platelet-derived  growth  factor 
PEG         Polyethylenglycole 
PI3K          Phosphatidylinositol  3-kinase 
PIP2          Phosphatidylinositol-4,5-diphosphate 
PKC         Protein  kinase  C 
PLC         Phospholipase  C 
PMSF         Phenylmethylsulfonyl-fluoride 
PNPP         p-Nitrophenyl-phosphate 
PTP       Protein  tyrosine  phosphatase   
P T X          P e r t u s s i s   t o x i n  
PY         Phospho-tyrosine 
Raf         Homologue  to  v-raf  (murine  sarcoma  viral 
oncogene) 
Ras             Homologue to v-ras (rat sarcoma viral oncogene) 
RNA         Ribonucleic  acid 
ROS       Reactive  oxygen  species 
rpm         Rotations  per  minute 
RT         Room  temperature 
RTK         Receptor  tyrosine  kinase 
SAPK         Stress-activated  protein  kinase 7. Abbreviations    98 
 
S.  D.         Standard  deviation 
SDS         Natriumdodecylsulfate 
SDS-PAGE        SDS  polyacrylamide  gel  elektrophoresis 
Sec         Second 
SH2,  3       domain  Src homology 2, 3 domain 
SHP-2         SH2-containing  PTP-2 
Sos         Son  of  sevenless 
Src             Homologue to v-src (sarcoma viral oncogene) 
T A C E          T N F α-converting enzyme 
TCA         Trichloroacetic  acid 
T C F        T   c e l l   f a c t o r  
TGFα          Transforming growth factor alpha 
TEMED        N,  N,  N‘,  N‘-Tetramethyletylendiamine 
TMPS       Triple-membrane-passing-signal 
TNFα                 Τ umor necrosis factor alpha 
TPA         12-O-Tetradecanoyl-phorbol-13-acetate 
Tris         Tris(hydroxymethyl)aminomethan 
Tween  20        Polyoxyethylensorbitanmonolaureate 
U         Enzymatic  activity  unit 
O/N         Overnight 
UV         Ultraviolett 
V          V o l t  
VEGFR      Vascular  endothelial growth factor receptor 
V o l          V o l u m e  
W t          W i l d   t y p e     
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